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Reporting bias threatens the validity of evidence. This dissertation addressed three types of 
reporting bias, i.e., primary outcome switching, language bias, and duplicate publication bias 
among randomized controlled trials (RCTs) from mainland China. 
Method 
RCTs that evaluated the efficacy and/or safety of drug interventions and were conducted in 
mainland China between 2008 and 2014, were retrieved from trial registries, and their 
corresponding journal articles were identified from both English and Chinese bibliographic 
databases. 
First, we evaluated the association between the findings of registered primary outcomes 
(positive vs. negative) and the switching of registered primary outcomes (registered primary 
outcomes switched to secondary outcomes in the journal articles vs. registered primary 
outcomes remained primary in the journal articles). Second, we evaluated the association 
between the finding of RCTs (positive vs. negative) and the language of corresponding journal 
articles published subsequently (English vs. Chinese). Third, we evaluated the association 
between the findings of RCTs (positive vs. negative) and the occurrence of subsequent 
duplicates.  
Results 
When RCTs were prospectively registered, the odds of switching primary outcomes with 
negative findings were 2.34 (95%CI: 1.03 to 5.33) times the odds of switching primary outcomes 
with positive findings. When RCTs were retrospectively registered before trial completion, the 
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odds of switching primary outcomes with negative findings were 9.69 (95%CI: 3.62 to 25.93) 
times the odds of switching primary outcomes with positive findings. 
Among RCTs registered in bilingual registry, RCTs with positive findings were 3.92 (95%CI: 
2.20-7.00) times more likely to be published in English than those with negative findings; among 
RCTs registered in English registries, RCTs with positive findings were 3.22 (95%CI: 1.34-7.78) 
times more likely to be published in English than those with negative findings.  
When the main articles of RCTs were published in Chinese, those with positive findings were 
2.48 (95%CI: 1.08 – 5.71) times more likely to have subsequent duplicates than those with 
negative findings. 
Conclusion 
We found evidence supporting the three types of reporting bias among RCTs from mainland 
China, which may threaten the validity of evidence synthesized by systematic reviews. 
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1. Proliferating RCTs from Mainland China 
Mainland China has become the largest producer of scientific publications since 2016, 
surpassing the United States.1 Meanwhile, the number of RCTs from mainland China has 
increased from 16,000 in 2006 to more than 44,000 in 2016 [YJ, Jun Liang, JW, et al, 
unpublished data, June 2020]. Owing to the language barrier, more than 90% of those RCTs 
are published in Chinese and only indexed in Chinese bibliographic databases. 
 
2. Reporting Bias as A Threat to the Evidence 
Findings of RCTs should be neutrally disseminated to the academic society. However, it was 
revealed that in the Western world investigators may selectively report or suppress findings of 
RCTs based on their nature and direction. For example, investigators may selectively report 
statistically significant (also referred to as 'positive') findings supporting the hypothesis of the 
study. Such selective reporting or suppressing of findings may introduce bias into evidence 
synthesis practice, i.e., reporting bias.2 
For example, it is well established that clinical trials with positive findings are more likely to be 
published than those with negative findings, i.e., publication bias;3,4 in non-English-speaking 
countries, clinical trials with positive findings are more likely to be published in English than 
those with negative findings, i.e., language bias;5 clinical trials with positive findings are more 
likely to be published multiple times than those with negative findings, i.e., duplicate publication 
bias;6,7 clinical trials with positive findings are more likely to be published in high impact journals 
than those with negative findings, i.e., location bias;8 clinical trials with positive findings are more 
likely to be cited by subsequent studies than those  (citation bias);9 and clinical trials with 
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positive results are more likely to be published more rapidly than those with negative results, 
i.e., time lag bias.10,11In addition, in individual clinical trials, outcomes with positive findings are 
more likely to be published than those with negative findings.12 
Besides the seven types of reporting bias defined in the Cochrane Handbook, we consider 
primary outcome switching as another type of reporting bias owing its similar mechanism of 
occurrence. Primary outcome switching is defined as the phenomenon that registered primary 
outcomes with negative findings are more likely to be downgraded to secondary outcomes in 
the subsequent publications than those with positive findings.4 Switching primary outcomes 
based on the nature of findings may artificially amplify the probability of false positive findings, 
bias the interpretation of the overall result, and lead to adoption of new therapies with spurious 
benefits.13-15 
Reporting bias overexposes positive findings to researchers who may subsequently 
overestimate treatment effects of health interventions in systematic reviews and clinical practice 
guidelines, eventually leading to suboptimal health care decisions detrimental to patients.  
 
3. Trial Registries Can Be Used to Evaluate Reporting Bias 
Trial registries are standardized and free-of-charge platforms that document key protocol 
information of clinical trials, such as participants, interventions, and outcomes.16 All clinical trials, 
regardless of design and sponsorship, should be registered before recruitment starts.17 Any 
subsequent change of clinical trial protocols should be documented as well.  
Trial registries can help researchers reduce the impact of reporting bias by identifying all 
relevant clinical trials regardless of their publishing status.18 Meanwhile, trial registries make it 
possible for researchers to trace and audit the change of clinical trial protocols over time.19 
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Trial registration has been widely supported by the academic community and the legal 
authorities. In 2004, the International Committee of Medical Journal Editors announced that they 
would not publish reports of clinical trials unless they had been appropriately registered.17 The 
28th China Food and Drug Administration (China FDA) Announcement in 2007 mandated pre-
registration of clinical trials conducted in mainland China on the Drug Clinical Trial Registration 
Platform (DCTRP) before recruitment started.20 These actions have substantially prompted 
registration of RCTs from mainland China.21  
 
4. Research Gap of Previous Studies 
Although there has been abundant literature on reporting bias regarding RCTs, very few have 
been dedicated to RCTs from mainland China, therefore little is known on whether reporting 
bias exists or to what extent among RCTs from mainland China. Owing to different linguistic 
systems, academic structures, legislations, and research cultures, it may not be valid to directly 
extrapolate the findings from the Western world to mainland China. Given the number of RCTs 
conducted in China of relevance globally, it is urgent to conduct research on the existence of 
reporting bias among RCTs from mainland China and estimate how much this bias may affect 
the current evidence synthesis practice. 
We propose a retrospective cohort study to evaluate the existence of three types of reporting 
bias among RCTs from China: primary outcome switching, language bias, and duplicate 
publication bias. Primary outcome switching, i.e., registered primary outcomes with positive 
findings are more likely to be switched in the subsequent publications than those with negative 




5. Study Aims 
Aim 1.  To assess the association between the switching of registered primary outcomes 
(registered primary outcomes switched to secondary outcomes in the published journal articles 
vs. registered primary outcomes that remained primary in the published journal articles) and the 
findings of the registered primary outcomes (positive vs. negative) among RCTs from mainland 
China. We will compare the primary outcomes from trial registries with the corresponding 
outcomes published in the journal articles.  
Hypothesis: Registered primary outcomes with negative findings are more likely to be 
downgraded to secondary outcomes in the journal articles than those with positive findings. 
Aim 2.  Assess (1) the association between the findings of RCTs (positive vs. negative) and the 
language of corresponding journal articles published subsequently (English vs. Chinese) and (2) 
the association between the findings of RCTs (positive vs. negative) and the language of the 
bibliographic databases where the journal articles were indexed (English vs. Chinese) among 
RCTs from mainland China.  
Hypothesis: (1) RCTs with positive findings are more likely to be published in English than those 
with negative findings; (2) RCTs with positive findings are more likely to be indexed in English 
bibliographic databases than those with negative findings. 
Aim 3.  Describe the patterns of duplicate publications and assess the association between the 
findings of RCTs (positive vs. negative) and the occurrence of subsequent duplicate 
publications (having vs. not having subsequent duplicate publications).  
Hypothesis: RCTs with positive findings are more likely to have subsequent duplicate 




6. Dissertation Data Source 
All the data in this dissertation are collected from public-available sources. There is no need to 
request approval from the institutional review board. 
RCTs from mainland China are retrieved from trial registries, including the primary registries 
recognized by the World Health Organizations and DCTRP sponsored by the China FDA.22 The 
corresponding journal articles are identified from seven bibliographic databases, three English 
ones (PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL)); 
and four Chinese ones: the China National Knowledge Infrastructure (CNKI), SinoMed, the VIP 
information, and the Wanfang Data).23 
 
7. Dissertation Structure 
This dissertation has three chapters and a conclusion. Each chapter is formatted as a 
publishable manuscript. Chapter 1 assesses the switching of primary outcomes. Chapter 2 
assesses language bias and indexing bias. Chapter 3 develops patterns of duplicates and 
assesses duplicate publication bias.  The conclusion summarizes the findings and outlines next 
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Abstract 
Importance Switching primary outcomes based on the findings may lead to biased 
interpretation of trial results and adoption of therapies with spurious benefits. 
Objective To evaluate whether among randomized clinical trials (RCTs), registered primary 
outcomes with negative findings were more likely to be switched to secondary outcomes in the 
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published journal articles than those with positive findings, and whether this association was 
modified by the timing of registration. 
Design  Retrospective cohort study. 
Settings Trial registries and bibliographic databases. 
Participants RCTs sponsored by organizations located in mainland China conducted between 
2008 and 2014. Eligible RCTs were retrieved from trial registries and the journal articles were 
identified from bibliographic databases until August 2019. 
Exposure Findings of primary outcome (positive vs. negative). 
Main Outcomes and Measures Registered primary outcome being switched to secondary 
outcome in the journal article. The timing of registration (prospective registration vs. 
retrospective registration before trial completion vs. retrospective registration after trial 
completion) was pre-specified as an effect-modifier. 
Results  Switching of primary outcomes occurred in 130 of 294 (44.2%) included 
RCTs. None of the articles mentioned the switching or provided justification. 
429 registered primary outcomes were mapped to 1354 published outcomes, including 528 
(39.0%) primary outcomes and 826 (61.0%) secondary outcomes. The main analysis supported 
the association between the nature of findings and the switching of primary outcomes (F=10.0, 
P<0.01) and the timing of registration as an effect modifier (F=6.8, P<0.01). When RCTs were 
prospectively registered, the odds of switching primary outcomes with negative findings were 
2.34 (95%CI: 1.03 to 5.33) times the odds of switching primary outcomes with positive findings. 
When RCTs were retrospectively registered before trial completion, the odds of switching 
primary outcomes with negative findings were 9.69 (95%CI: 3.62 to 25.93) times the odds of 
switching primary outcomes with positive findings.  
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Conclusion and Relevance Registered primary outcomes with negative findings are more 
likely to be switched to secondary outcomes in the published journal articles. The timing of 
registration modifies this association as the strongest effect is observed among RCTs 
retrospectively registered before trial completion. Prospective registration should be promoted to 
detect and reduce primary outcome switching. 
 
Introduction 
Randomized controlled trials (RCTs), the pillar of evidence-based medicine, are a key tool to 
evaluate the efficacy and safety of health care interventions. An RCT usually incorporates 
multiple outcomes, of which the primary outcome is especially important to informing the 
overarching design, analysis, and interpretation.1 Ideally, primary outcomes should be pre-
specified and registered before the first participant is enrolled.2,3 Any subsequent modification 
should be appropriately documented and reported to the research community.  
Switching primary outcomes after recruitment has begun is prevalent.4-6 Several factors, such 
as the sponsorship or financial ties related to the industry, may drive these changes.7,8 Another 
factor which is widely suspected to influence primary outcome switching is the nature of findings 
as they develop; that is, whether the findings of primary outcomes are positive or statistically 
significant.5 Switching primary outcomes based on the nature of findings may artificially amplify 
the probability of false positive findings, bias the interpretation of the overall result, and lead to 
adoption of new therapies with spurious benefits.6,9,10 
Trial registries enable investigators to track the changes of primary outcomes over the course of 
a trial and scrutinize any discrepancies between trial protocols and subsequent publications.11-
13Recently trial registries have been witnessing a proliferation of RCTs from China.14,15 Trialists 
in China can register RCTs either in English registries, such as ClinicalTrials.gov (CT.gov), or 
9 
 
bilingual registries, such as the Chinese Clinical Trial Registry (ChiCTR). The versatility and 
dispersion of these RCTs provides a unique opportunity to evaluate the switching of primary 
outcomes and potential effect modifiers. The aim of this analysis is to evaluate the association 
between the nature of findings and the switching of primary outcomes, and whether this 
association varies by registry and the timing of registration. 
 
Methods 
In this retrospective cohort study, we retrieved RCTs sponsored by organizations located in 
mainland China from trial registries, identified the corresponding journal articles from 
bibliographic databases, compared the primary outcomes between trial registries and journal 
articles, and evaluated the factors associated with primary outcome switching. We followed the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting 
guideline.16 The study was not subject to institutional review board approval because all the 
data were open-source and no participant was involved. 
Retrieve RCTs from Trial Registries 
The method to retrieve registry records and journal articles of RCTs is described elsewhere.17 
Briefly, we retrieved RCTs from 17 primary registries recognized by the World Health 
Organization and the Drug Clinical Trial Registry Platform (DCTPR) sponsored by the China 
Food and Drug Administration (China FDA).18,19 RCTs were retrieved if they evaluated drugs 
that were regulated by the United States Food and Drug Agency (US FDA) and/or the European 
Medicine Agency (EMA).20,21 We only considered RCTs conducted between January 1, 2008 
and December 31, 2014 to allow a minimum of 4.5 years from trial completion to publication.22  
Identify Journal Articles from Bibliographic Databases 
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The corresponding journal articles from registered RCTs were searched through seven  
bibliographic databases, including PubMed, Embase, the Cochrane Central Register of 
Controlled Trials, the China National Knowledge Infrastructure (CNKI), SinoMed, the VIP 
information, and the Wanfang Data.23 The search strategy, search terms, and the method to 
match registry records to journal articles are shown in Supplement Tables 1-3. We only included 
the main article of each RCT, defined as the article with the largest sample size, or the earliest 
article submitted to a journal if identical sample size was reported in multiple articles. The 
screening was conducted by two authors (YJ and DH) independently and adjudicated by a third 
author (JW) in case of discrepancy.  
Map primary outcomes from Trial Registries to Journal Articles 
We extracted all the outcomes labelled as 'primary' from trial registries and dissected them into 
five elements including domain (e.g., systolic blood pressure), specific measurement (e.g., a 
device at sitting position), specific metric (e.g., change from baseline), method of aggregation 
(e.g., mean or median), and time-points.24 Registered primary outcomes were excluded if (1) the 
domain was not specified, such as 'efficacy', 'safety', etc.; (2) not related to the study 
intervention, e.g., baseline characteristics, etc.; and (3) duplicated with previous primary 
outcomes in the same trial. If RCTs were prospectively registered, i.e., registration occurred 
before recruitment started,11 we only considered the latest version before recruitment started; if 
the RCTs were retrospectively registered, i.e., registration occurred after recruitment started, we 
only considered the earliest version. 
Two authors (YJ and DH) independently searched the articles for published outcomes that were 
consistent with a registered primary outcome in terms of the elements. A registered primary 
outcome might fail to specify one or more elements and thus could be mapped to multiple 
published outcomes. For example, the registered primary outcome of 'the change of systolic 
blood pressure from baseline', which lacked time-points, could be mapped to the published 
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outcomes measured at multiple time-points in the articles. We did not consider outcomes 
measured among subgroups.  
Analysis plan 
Exposure    The exposure was the nature of findings of registered primary outcomes (positive 
vs. negative). We defined positive findings as favoring the study hypothesis with statistical 
significance. For example, a superiority trial was positive when the experimental drug was 
significantly superior over the comparator. We defined negative findings as not statistically 
significant or contradictory to the study hypothesis. 
Outcome    The outcome of this study was defined as a registered primary outcome of an RCT 
being switched to a secondary outcome in the published journal article. In the main analysis, we 
considered an outcome in an article as 'primary' if it was designated as such or used in the 
power calculation in case of no designation.  
Effect Modifiers We classified the timing of registration into three categories: (1) 
prospective; (2) retrospective before trial completion, i.e., the trial was registered after 
recruitment started but before it was completed; and (3) retrospective after trial completion, i.e., 
the trial was registered after it was completed. We assumed the association between the nature 
of findings and primary outcome switching would be the strongest when RCTs were 
prospectively registered, while the weakest when RCTs were retrospectively registered after 
trial completion, because we expected those registered retrospectively could have already 
switched primary outcomes before registration. We also hypothesized that the association 
between the nature of findings and primary outcome switching might vary across registries. 
Confounders Three possible confounders were pre-specified, including funding source 
(industry vs. non-industry), sample size (>=100 or <100), and number of recruiting centers per 
trial (multiple vs. single).7,8,25,26 
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Measurements of Associations    We hypothesized that registered primary outcomes with 
negative findings were more likely to be downgraded to secondary outcomes in the articles than 
those with positive findings. Odds ratio (OR) were estimated by multi-level logistic models with 
random intercept to account for two levels of correlation: multiple registered primary outcomes 
within the same trial and multiple published outcomes mapped from the same registered 
primary outcome. Considering outcome reporting bias, i.e., negative outcomes are less likely to 
be published than positive outcomes, the assumption of data missing at random would not hold 
in case a registered primary outcome was missing from the article. Thus, the main analysis was 
conducted on complete cases, while two sensitivity analyses were conducted on the best-case 
and worst-case scenarios regarding the missingness, respectively. 
We conducted two comparisons across registries: (1) the average number of registered primary 
outcomes per trial; (2) the proportion of registered primary outcomes with specified time-points.3 
We also compared the outcomes reported as 'primary' with the ones used in power calculations 
in the articles. 
In the first sensitivity analysis, we only considered outcomes designated as primary in the 
articles, while excluding the ones identified from power calculations because we expected 
differences between those two methods of identifying primary outcomes. In the second 
sensitivity analysis, the registered primary outcomes missing from the articles were explored 
under a worst-case scenario: If a registered primary outcome was published as primary in the 
article with unclear findings, we assumed it to be negative; If a registered primary outcome was 
reported as secondary in the article with unclear findings, we assumed it to be positive; If a 
registered primary outcome was completely missing from the article, we assumed it to be 
published as secondary and positive. The third sensitivity analysis explored the best-case 
scenario against all the assumptions in the second sensitivity analysis. 
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The between-group comparisons were conducted by Mann-Whitney test. Statistical significance 
was defined as a P value less than 0.05 for the main effect and 0.1 for interaction. SAS® 9.4 
was used for data cleaning and analysis. 
 
Results 
Characteristics of Included RCTs 
The search of trial registries and bibliographic databases was conducted from March to August 
2019 (Figure 1). In total 891 RCTs evaluating drug(s) were retrieved from registries, of which 
470 (52.7%) were matched to at least one journal article. We subsequently excluded 203 RCTs 
owing to missing registration date (n=16), unclear primary outcome in the registry (n=5), or 
unclear primary outcome in the article (n=155). 294 RCTs were included in the analysis, 
including 187 from ChiCTR, 103 from CT.gov, and 4 from ISRCTN. RCTs from CT.gov and 
ISNCTR were combined to form a new category referred to as English registries. 
The characteristics of included RCTs are shown in Table 1. More than a third of RCTs were 
prospectively registered (113/294, 38.44%), followed by retrospective registration before trial 
completion (108, 36.73%) and retrospective registration after trial completion (73, 24.83%). 
Most RCTs were funded by non-industrial organizations (237, 80.61%), recruited more than 100 
participants (194, 65.99%), and were conducted in a single institution (198, 67.35%). 
Meanwhile, RCTs from ChiCTR registered more primary outcomes than English registries (2.40 
vs. 1.20, χ2=38.52, P<0.01). 47 (25.13%) RCTs from ChiCTR registered at least 3 primary 
outcomes, higher than English registries (OR=6.85, 95%CI: 2.63-17.83), where only 5 (4.67%) 
registered at least 3 primary outcomes. 
Elements of Registered Primary Outcomes 
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A total of 577 primary outcomes were retrieved from the registries, including 449 (77.82%) from 
ChiCTR and 128 (22.18%) from English registries. Only 3.56% primary outcomes from ChiCTR 
included the time-points, much lower than English registries (96.09%). 
Discrepancy between Primary Outcome Designation and Power Calculation 
In 182 articles the authors simultaneously designated primary outcomes and reported power 
calculations regarding 496 outcomes in total. 246 (49.60%) primary outcomes were both 
designated and used in power calculations, 236 (47.58%) were designated but missing from 
power calculations, while 14 (2.82%) were used in power calculations but not designated as 
primary outcomes. 
Discrepancies between Trial Registries and Journal Articles 
We detected primary outcome switching in 130 of 294 (44.20%) RCTs, including 103 (55.08%) 
from ChiCTR and 27 (25.23%) from English registries. None of the articles provided a rationale 
for the switching. Among the 577 registered primary outcomes, 429 (74.35%) were mapped to 
1354 published outcomes in the articles, including 528 (39.00%) primary outcomes and 826 
(61.00%) secondary outcomes. The remaining 148 (25.65%) registered primary outcomes were 
considered missing.  
The main analysis supported the association between the nature of findings and primary 
outcome switching (F=9.99, P<0.01), along with the timing of registration being an effect 
modifier (F=6.76, P<0.01). However, we did not find evidence supporting that the association 
between the nature of findings and primary outcome switching varied in registries (F=0.21, 
P=0.65). When the RCTs were prospectively registered, the odds of switching primary 
outcomes with negative findings were 2.34 (95%CI: 1.03 – 5.33) times the odds of switching 
primary outcomes with positive findings. When the RCTs were retrospectively registered before 
trial completion, the odds of switching primary outcomes with negative findings were 9.69 
15 
 
(95%CI: 3.62 – 25.93) times the odds of switching primary outcomes with positive findings. The 
ORs were consistent across registries while the magnitude was slightly higher among RCTs 
from ChiCTR (Table 2). 
There was evidence supporting the registry and the number of recruiting centers as two 
confounders, i.e., the odds of switching primary outcomes from ChiCTR was 5.11 (95%CI: 2.32 
– 11.26) times the odds of switching primary outcomes from English registries; the odds of 
switching primary outcomes from RCTs conducted in one recruiting center was 2.79 (95%CI: 
1.11-7.02) times the odds of switching primary outcomes from RCTs conducted in multiple 
recruiting centers.  
The first sensitivity analysis produced similar results to the main analysis, although the 
magnitude of associations decreased slightly (Supplemental Table 4). The second sensitivity 
analysis under the worst-case scenario still supported the association between the nature of 
findings and primary outcome switching among RCTs which were retrospectively registered 
before trial completion (Supplemental Table 5). The third sensitivity analysis reaffirmed the 
findings from the main analysis with strengthened associations (Supplemental Table 6). 
 
Discussion 
Our study supported the hypothesis that trialists were more likely to downgrade a registered 
primary outcome to a secondary outcome in publications if the findings were negative.  
We found that 26% of RCTs from English registries (mainly CT.gov) switched primary outcomes 
– a percentage slightly lower than a previous study, in which 31.7% of clinical trials from CT.gov 
switched primary outcomes after registration.4 We observed a much higher probability of 
primary outcome switching among RCTs from ChiCTR (55%), mainly because in ChiCTR, 
RCTs tended to register multiple primary outcomes. The overall percentage of switching (44%) 
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was comparable to cohorts of trials submitted to ethics committees.27-30 However, we only 
measured one type of switching. It is likely that the overall frequency of primary outcome 
switching would be higher than RCTs outside of China if we had considered all possible types of 
switching, e.g., a registered secondary outcome was upgraded to a primary outcome in the 
publication or a new outcome never appearing in the registry was added as a primary outcome 
in a publication.27 
We also hypothesized that the stage of recruitment at the time of registration (i.e., prospective 
or retrospective registration) would be related to the likelihood of switching primary outcomes. 
We assumed that before the first patient was enrolled, the findings were challenging to predict, 
therefore a subsequent switching was possible when the findings of the registered primary 
outcome were negative. On the other hand, as recruitment began and continued, data from 
participants gradually accumulated to facilitate trialists to predict the findings. At this stage, 
trialists would be able to register an outcome, which was likely to bear positive findings, as 
primary in the registry, thereby reducing the risk of switching it thereafter. However, our analysis 
contradicted this assumption, instead suggesting the strongest association was among trials 
registered retrospectively rather than at the beginning of a trial. A possible explanation is that 
trialists who registered their trials beforehand might be more aware of the guidelines and 
regulations to conduct high-quality trials and thus were more willing to abide by the rules and 
retain the pre-defined primary outcomes regardless of the findings.  
We also hypothesized that the association between the nature of findings and the likelihood of 
switching primary outcome varied across registries because ChiCTR was different from English 
registries in many aspects; for example, our study showed the data quality was much better in 
English registries than ChiCTR in terms of specifying time-points. Despite the differences, we 
found little evidence supporting the heterogeneity in the association across registries. This 
suggests that improving data quality of registries may not reduce the association between the 
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nature of findings and primary outcome switching. However, we did find evidence supporting 
that primary outcome switching occurred more often among RCTs from ChiCTR, which may be 
attributable to the tendency of defining multiple primary outcomes. 
Our study reiterated the importance of registering clinical trials prospectively to enable the 
medical community to track and audit any changes over time.11,13,31 Currently less than 15% of 
RCTs were registered,32 of which more than half were retrospective registration,17 posing a 
serious challenge to researchers and policy makers. Although China FDA – the only 
government agency supervising clinical trials in China – has required registration of clinical trials 
submitted in support of marketing license of medical products since 2013,19 such trials 
constitute only a small fraction of all trials in China, where publications have been dominated by 
post-marketing trials. Promoting and expanding registration would be the most effective 
approach to addressing the problem, either by legislation from government agencies or broad 
requirement by research institutes and academic journals. Unfortunately, registration can only 
facilitate detecting, rather than reducing, the switching of primary outcomes.11 Other smaller 
step may be more actionable and have an impact: none of the articles in our study mentioned or 
justified their switching of primary outcomes, implying that this had been overlooked by 
reviewers and journal editors. We recommend reviewers to routinely compare registry with 
manuscript of RCTs. Authors should be required by either reviewers or journal editors to explain 
any discrepancies identified. 
Our study has several limitations. First, a larger sample would enable more precise estimation 
of the associations. Second, a quarter of the registered primary outcomes were missing from 
the linked publications. Although we demonstrated the robustness of the main analysis by 
assuming a worst-case scenario, the complete-case analysis would likely underestimate the 
associations due to outcome reporting bias,27 the 'real' association including the missing primary 
outcomes should be somewhere between the main analysis and sensitivity analysis under the 
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best-case scenario. Third, although we developed a systematic method to search the literature 
and match journal articles, it is possible that we mismatched or overlooked some articles. 
Fourth, we allowed RCTs at least 4.5 years from trial completion to publication, which might not 
be adequate in some cases. Considering the large effect size, we believe capturing a few more 
trials would be unlikely to affect our conclusions. Finally, we restricted our study sample to 
RCTs that evaluated drugs only within mainland China. It is unclear whether our conclusions 
can be extrapolated to other interventions, such as traditional Chinese medicine, or RCTs 
outsides of China.33 Future research is needed to explore the association in other settings, more 
factors playing a role in the association, and whether the association changes overtime. 
 
Conclusion 
Our study supports the hypothesis that the nature of findings plays a role in the likelihood of 
changing primary outcome among RCTs. Additionally, the timing of registration modifies this 






Table 1  Characteristics of Included RCTs 
Characteristics Category ChiCTR English Registries Total No. % No. % No. % 
        
Number  187 100 107 100 294 100 
        
Timing of Registration Prospective 73 39.04 40 37.38 113 38.44 
 Retrospective Before Trial Completion 60 32.09 48 44.86 108 36.73 
 Retrospective After Trial Completion 54 28.88 19 17.76 73 24.83 
        
Funding Industry 37 19.79 20 18.69 57 19.39 
 Non-Industry 150 80.21 87 81.31 237 80.61 
        
Sample Size <100 66 35.29 34 31.78 100 34.01 
 >=100 121 64.71 73 68.22 194 65.99 
        
Number of Centers Multiple 50 26.74 46 42.99 96 32.65 
 Single 137 73.26 61 57.01 198 67.35 
        
No. of Registered Primary Outcomes Single Primary Outcome 98 52.41 94 87.85 192 65.31 
 2 Co-Primary Outcomes 42 22.46 8 7.48 50 17.01 
 >=3 Co-Primary Outcomes 47 25.13 5 4.67 52 17.69 
Abbreviations 
RCT: Randomized Controlled Trials; ChiCTR: Chinese Clinical Trial Registry; OR: Odds Ratio 
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Table 2    Factors Associated with Discrepancy between Registered and Published Primary Outcomes:  
Primary Analysis 
Factor Level Stratum OR 95%CI P Value 
Nature of the Findings Negative vs. Positive  
Prospective Registration 2.34 1.03 – 5.33 0.04 
Retrospective Before Trial Completion 9.69 3.62 – 25.93 <0.01 
Retrospective After Trial Completion 0.80 0.30 – 2.13 0.66 
    
ChiCTR & Prospective Registration 2.69 1.27 – 5.73 0.01 
ChiCTR & Retrospective Before Trial Completion 11.16 3.95 – 31.49 <0.01 
ChiCTR & Retrospective After Trial Completion 0.93 0.37 – 2.29 0.87 
    
English Registries & Prospective Registration 2.03 0.59 – 6.95 0.26 
English Registries & Retrospective Before Trial Completion 8.41 2.38 – 29.67 <0.01 
English Registries & Retrospective After Trial Completion 0.70 0.18 – 2.68 0.6 
      
Registry ChiCTR vs. English Registries 5.11 2.32 – 11.26 <0.01 
     
Timing of Registration Prospective vs. Retrospective After Trial Completion 0.52 0.22 – 1.20 0.13 Retrospective Before Trial Completion vs. Retrospective After Trial Completion    
  0.51 0.23 – 1.15 0.11 
Sample Size >=100 vs. <100 0.52 0.25 – 1.08 0.08 
     
Funding Non-Industry vs. Industry 1.12 0.41 – 3.03 0.83 
     
Number of Recruiting Centers Single vs. Multiple 2.79 1.11 – 7.02 0.03 
Abbreviations 
ChiCTR: Chinese Clinical Trial Registry; OR: Odds Ratio 
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Eligible RCTs    N=891 
Registry Records Evaluated for Eligibility    N=5,084 
Excluded N=4,181 
Not on Drug N=1,766 
Not RCT N=374 
Missing Information    N=188 
Non-Chinese Sponsor or PI    N=342 
Outranged Study Period   N=939 
Phase 1 Trials    N=566 
Intra-Registry Duplicates    N=6 
Inter-registry Duplicates    N=12 
Published RCTs    N=470 
Excluded    N=421 
• Unpublished RCTs   N=421 
Excluded    N=176 
• Missing Registration Date   N=16 
• Unclear Primary Outcome in Trial Registry    N=5 
• Unclear Primary Outcome in Journal Article    N=155 
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Abstract 
Importance Language bias and indexing bias may exist among Chinese-Sponsored 
Randomized Controlled Trials (CS-RCTs). Such bias may threaten the validity of systematic 
reviews. 




Design In this retrospective cohort study we retrieved eligible CS-RCTs from trial 
registries and searched bibliographic databases to determine their publication status. The 
search and analysis were conducted from March to August 2019. 
Setting Primary trial registries recognized by the World Health Organization (WHO) and 
the Drug Clinical Trial Registry Platform (DCTRP) sponsored by the China Food and Drug 
Administration (China FDA). 
Participants Eligible CS-RCTs were on drug interventions and conducted between January 
2008 and December 2014. 
Exposure Individual CS-RCTs with positive (versus negative) results. 
Main Outcomes and Measures For assessing language bias, the main outcome was the 
language of the journal where CS-RCTs were published (English versus Chinese). For indexing 
bias, the main outcome was the language of bibliographic database where the CS-RCTs were 
indexed (English versus Chinese). 
Results    We identified 891 eligible CS-RCTs. Four hundred and seventy CS-RCTs were 
published by August 2019, of which 368 (78.3%) were published in English. Among CS-RCTs 
registered in the Chinese Clinical Trial Registry (ChiCTR), positive CS-RCTs were 3.92 (95%CI: 
2.20-7.00) times more likely to be published in English than negative CS-RCTs; among CS-
RCTs registered in English registries, positive CS-RCTs were 3.22 (95%CI: 1.34-7.78) times 
more likely to be published in English than negative CS-RCTs. These findings suggest the 
existence of language bias. Among CS-RCTs registered in ChiCTR, positive CS-RCTs were 
2.89 (95%CI: 1.55-5.40) times more likely to be indexed in EBDs than negative CS-RCTs; 
among CS-RCTs registered in English registries, positive CS-RCTs were 2.19 (95%CI: 0.82-
5.82) times more likely to be indexed in EBDs than negative CS-RCTs. These findings support 
the existence of indexing bias.  
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Conclusions and Relevance Our study indicates the existence of language bias and 
indexing bias among registered CS-RCTs on drug interventions. This may distort evidence-
synthesis towards more positive results of drug interventions. 
 
Introduction 
In non-English-speaking countries, researchers can choose to publish randomized controlled 
trials (RCTs) in either English journals or journals in their native language. It is established that 
RCTs with positive results ("positive RCTs") are more likely to be published in English journals: 
a phenomenon termed language bias 1. This tendency may lead to disproportionally more 
positive RCTs in the English literature and consequently more negative RCTs in the non-English 
literature 2. 
Ideally this bias would not threaten the validity of systematic reviews as reviewers should 
comprehensively search for all the existing evidence, regardless of the language 1; however, 
estimates indicate that almost 40% of systematic reviews are reportedly restricted to English 
language articles indexed in English bibliographic databases (EBDs) 3. This raises the concern 
that such reviews may miss negative RCTs which are only published in the non-English 
literature, leading to biased evidence 4. 
Recently scientific publications from Mainland China have been surging 5. Publications of RCTs 
sponsored by researchers in Mainland China, referred to as CS-RCTs, are also split between 
English and Chinese journals ("English CS-RCTs" and "Chinese CS-RCTs") 6. However, limited 
evidence is available regarding language bias among CS-RCTs. It's unknown whether we 




A further challenge, and one which is more difficult to address, is that most Chinese journals 
have not been indexed in EBDs due to large quantity and varying quality 7. This implies that 
systematic reviewers have to not only remove language restrictions from searching EBDs but 
also actively search Chinese bibliographic databases (CBDs) to capture all Chinese CS-RCTs, 
a practice seldomly adapted by the systematic review community 8. Bias may exist if Chinese 
CS-RCTs with positive results are more likely to be indexed in EBDs than their negative 
counterparts which are more commonly seen in CBDs. We refer this potential residual of 
language bias to indexing bias. 
Currently the Cochrane Handbook for Systematic Reviews of Interventions only recommends 
searching CBDs for systematic reviews of Chinese herbal medicine 1. It’s unknow whether the 
recommendation should be extended to drug interventions. The objective of this study was to 
evaluate the existence of language bias and indexing bias among CS-RCTs on drug 
interventions to inform the potential update of the recommendation.  
 
Methods 
In this retrospective cohort study, we retrieved CS-RCTs from trial registries and searched 
bibliographic databases to determine their publication status. Two hypotheses were pre-defined: 
(1) positive CS-RCTs were more likely to be published in English than negative CS-RCTs 
(language bias), and (2) positive CS-RCTs were more likely to be indexed in EBDs (indexing 
bias). We followed the STROBE reporting guidelines 9. 
Identifying CS-RCTs from Trial Registries 
We retrieved CS-RCTs from all 17 primary registries recognized by the World Health 
Organization 10 and the Drug Clinical Trial Registry Platform (DCTPR) sponsored by the China 
Food and Drug Administration (China FDA) 11. 
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A substance was considered a drug if recognized and regulated by the United States Food and 
Drug Agency (US FDA) and/or the European Medicine Agency (EMA) 12,13. We included all CS-
RCTs that started after January 1, 2008 and completed before December 31, 2014 to allow a 
minimum of 4.5 years from trial completion to publication 14.  
We excluded Phase 1 trials (including bioequivalence and pharmacokinetics studies) and CS-
RCTs missing the study period or RCTs with an unclear study interval (e.g., end date before the 
start date), any unnamed experimental drug, principal investigator (PI), or sponsor in the 
registries. 
Identify Journal Articles from Bibliographic Databases 
We only included journal articles produced from eligible CS-RCTs. Conference abstracts, 
research letters, and dissertations were not included. Publications of protocols, subgroup 
analyses, secondary analyses, and meta-analyses were also excluded. 
Based on previous studies 14,15, we developed search strategies for individual CS-RCTs with 
informationists from the Welch Medical Library at the Johns Hopkins University and from the 
Institute of Information/Medical Library at the Peking Union Medical College (Supplement 1) 
16,17. We expanded the search terms with synonyms and spelling variations to increase 
sensitivity. The search terms were tailored and organized for each bibliographic database based 
on the database's specific syntax (Supplement 2). Seven bibliographic databases were 
subsequentially searched: three English ones (PubMed, Embase, and the Cochrane Central 
Register of Controlled Trials (CENTRAL)); and four Chinese ones: the China National 
Knowledge Infrastructure (CNKI), SinoMed, the VIP information, and the Wanfang Data) 18.  
We conducted a 4-step process to identify matches of eligible CS-RCTs. First, we searched 
bibliographic databases to retrieve citations; second, we screened the citations for eligible CS-
RCTs; third, we downloaded PDFs of possibly eligible trials; and fourth, we matched the PDFs 
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with the registry records of eligible CS-RCTs. The criteria for screening and matching are shown 
in Supplement 3.  
The journal articles were classified as confirmed matches and probable matches according to 
the similarity between journal articles and registry records. Confirmed matches indicated the 
journal articles were consistent with the registry records, while probable matches indicated the 
journal articles were similar to the registry records but differed on or lacked only one data item. 
The primary analysis was conducted among the confirmed and probable matches, while a 
sensitivity analysis was conducted among the confirmed matches only. 
Two authors independently searched bibliographic databases and identified matching PDFs of 
eligible CS-RCTs. Discrepancies were discussed and resolved by a third author. If multiple 
journal articles existed, we only considered the one with the largest sample size, or the earliest 
one if identical sample size was reported in multiple articles. 
Analysis plan 
Exposure    The exposure was the positivity of individual CS-RCTs (positive versus negative) 
according to the CS-RCT's primary outcome reported in the journal article(s) 19. If multiple 
primary outcomes were reported in a CS-RCT, we selected the first one reported in the result 
section. If no primary outcome was defined, the selection of the CS-RCT's primary outcome was 
based on the following hierarchical order: the first outcome used in the sample size calculation, 
the first outcome defined in the study objective, or the first outcome reported in the results 
section. When the time point was not specified for the CS-RCT's primary outcome which was 
measured at multiple time points, we considered the last time point in our main analysis and the 
first time point in sensitivity analyses. 
We defined a positive result as favoring the experiment group with statistical significance in 
superiority trials or showing no difference between treatment groups for equivalence or non-
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inferiority trials. Results which were not statistically significant, significantly favored the control 
group, or failed to show equivalence/non-inferiority were defined as negative.  
Outcome    Two main outcomes were defined: the language of the publication (English versus 
Chinese) and the language of the bibliographic database where the publication was indexed 
(English versus Chinese).  An article published in both Chinese and English was considered 
published in English; similarly, an article indexed in both EBDs and CBDs was considered 
indexed in EBDs. We assumed all English articles were indexed in EBDs, but Chinese articles 
were possibly indexed in EBDs or CBDs. 
Measurements of Associations   Bias was estimated by relative risk (RR), including point 
estimates and 95% confidence intervals (CIs). A RR larger than one indicated that positive CS-
RCTs were more likely to be published in English or indexed in EBDs than negative CS-RCTs. 
RRs were estimated using log binomial models with five covariates: sample size (<100 versus 
≥100), funding source (industry versus non-industry), study design (superiority versus non-
inferiority/equivalence), number of recruitment centers (single versus multiple), and registration 
type (prospective versus retrospective) 20-21. Industrial funding was considered as long as one 
funder was from industry; prospective registration was considered when registration occurred 
before the first participant was recruited 22. We included an interaction term in the models to 
evaluate the heterogeneity of bias across registries. Statistical significance was defined as a P 
value smaller than 0.05 for the main effect and 0.1 for interaction. SAS® 9.4 was used for data 
cleaning and analysis. 
 
Results 
The search through trial registries and bibliographic databases was conducted from March to 
August 2019. Among the 17 primary registries and DCTRP, five were found to include eligible 
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CS-RCTs: the Chinese Clinical Trial Registry (ChiCTR), ClinicalTrials.gov, ISRCTN, the 
Australia New Zealand Clinical Trials Registry (ANZCTR), and DCTRP. In total 5,084 CS-RCTs 
were retrieved from these trial registries and screened for eligibility. Eventually 891 eligible CS-
RCTs were identified, 470 (52.7%) of which had been published in 229 English journals and 72 
Chinese journals. The screening results are shown in Figure 1. 
Characteristics of CS-RCTs 
Among the 470 journal articles corresponding to 470 CS-RCTs, 368 (78.3%) were published in 
English, while 102 (21.7%) were in Chinese; 432 (91.9%) were confirmed matches to registry 
records, while 38 (8.1%) were probable matches. Thirty of 38 (78.9%) probable matches were 
published in Chinese. The matching results are shown in Supplement 3.  
The distribution of CS-RCTs across bibliographic databases is shown in Table 1. The three 
EBDs only indexed a small proportion of Chinese articles, ranging from 21.6% by PubMed to 
23.5% by Embase and CENTRAL. The low coverage of CNKI was mainly due to unindexed or 
partially unindexed medical journals sponsored by the Chinese Medical Association. 
Most (306, 65.1%) CS-RCTs were registered in ChiCTR, followed by ClinicalTrials.gov (143, 
30.4%), DCTRP (13, 2.8%), ISRCTN (4, 0.9%), and ANZCTR (1, 0.2%). The CS-RCTs in 
DCTRP, ISRCTN, and ANZCTR were too few to be analyzed separately. We expected that the 
two biases would be similar across ClinicalTrials.gov, ISRCTN, and ANZCTR, so we combined 
CS-RCTs from these three registries to form a new category: 'English registries'. On the other 
hand, DCTRP, which was only available in Chinese and was not a primary registry, was 
excluded from the inferential analyses.  
Of the 470 CS-RCTs, 323 (69.0%) were positive, 2 (0.4%) were excluded from inferential 
analyses due to unknown positivity (no inter-group comparison), 286 (60.9%) recruited at least 
100 participants, 322 (68.5%) were conducted at a single center, 377 (80.2%) were supported 
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by non-industry funding, 315 (67.0%) were retrospectively registered, and 442 (94.4%) were 
superiority trials.  
The distribution of covariates, including the sample size, funding source, study design, number 
of recruitment centers, and registration type, was similar between English and Chinese CS-
RCTs (Supplement 4); the distribution of covariates among CS-RCTs indexed in EBDs was 
similar to the ones only indexed in CBDs, although the number of positive CS-RCTs indexed in 
CBDs was slightly larger than the negative CS-RCTs (Supplement 5).  
Language Bias 
Four hundred and sixty-eight CS-RCTs were included for this analysis. As shown in Table 2, 
positive CS-RCTs were more likely to be published in English and were more likely to be 
indexed in EBDs than CS-RCTs published in Chinese. After adjusting for covariates, positive 
CS-RCTs were more commonly published in English than negative CS-RCTs. The RRs were 
3.92 (95%CI: 2.20-7.00) and 3.22 (95%CI: 1.34-7.78) among CS-RCTs registered in ChiCTR or 
English registries, respectively (Table 3). The interaction between registry and positivity of CS-
RCTs was not statistically significant (P=0.13), indicating no evidence of heterogeneity of 
language bias across registries. Other factors associated with increased likelihood of being 
published in English among CS-RCTs were sample size of >= 100 (RR 2.09; 95%CI: 1.19-3.67), 
single center as opposed to multicenter trial (RR 1.85; 95%CI: 1.01-3.41), and financial support 
from a non-industry source as compared to an industrial source (RR: 1.99; 95%CI: 1.06-3.75).  
Indexing Bias 
Four hundred and sixty-eight CS-RCTs were included for this analysis. As shown in Table 2, 
English CS-RCTs or CS-RCTs indexed in EBDs were more likely to be positive than Chinese 
CS-RCTs or CS-RCTs only indexed in CBDs. After adjusting for covariates, positive CS-RCTs 
were more commonly indexed in EBDs than negative CS-RCTs. The RRs were 2.89 (95%CI: 
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1.55-5.40) and 2.19 (95%CI: 0.82-5.82) among CS-RCTs registered in ChiCTR or English 
registries, respectively (Table 3). The interaction between registry and language of bibliographic 
databases was not statistically significant (P=0.22), indicating no evidence of heterogeneity of 
indexing bias across registries. The only other factor associated with an increased likelihood of 
being indexed in EBDs among CS-RCTs was sample size of > 100 (RR: 2.04; 95%CI: 1.11-
3.72). 
Sensitivity Analysis 
Two sensitivity analyses were conducted. When only confirmed matches (n = 432) were 
analyzed, the RRs increased regarding language bias (4.14 (95%CI: 2.09-8.21) among ChiCTR 
and 3.58 (95%CI: 1.32-9.72) among English registries) and decreased regarding indexing bias 
(2.47 (95%CI: 1.15-5.34) among ChiCTR and 1.92 (0.62-6.04) among English registries). When 
the first assessment  of the CS-RCTs' primary outcomes was analyzed (rather than the last 
assessment at the end of follow-up), the RRs increased regarding both language bias (5.34 
(95%CI: 3.00-9.68) among ChiCTR and 3.73 (95%CI: 1.53-9.07) among English registries) and 




Our study supports the existence of language bias and indexing bias among CS-RCTs 
registered in trial registries. As hypothesized, positive CS-RCTs were more likely to be 




Reputation, job prospects, as well as academic progress may critically depend on publishing in 
English journals among Chinese researchers 23,24. Positive CS-RCTs are more likely to be 
submitted to English journals as they typically have a higher chance of being accepted; 
accordingly, English journals contain more positive CS-RCTs than their Chinese counterparts.  
Theoretically, language bias disappears if all clinical trials shift to be published in English. This 
ideal has been echoed by a trend towards publishing in English in some countries, such as 
Germany 25. With the average number of RCTs per German journal decreasing from a 
maximum of 11.2 annually between 1970 and 1986 to only 1.7 annually between 2002 and 
2004, language bias from German-speaking countries may no longer be a concern.  
We did not detect such a trend among CS-RCTs. According to an ongoing study, the number of 
CS-RCTs published in Chinese may be as many as 44,000 in 2016, as opposed to fewer than 
1,000 being published in English 26. The deep gap between the Chinese and English literature 
has allowed significant space for language bias to develop. 
Several studies attempted to evaluate the effect of language bias based on non-English trials 
included in systematic reviews 27-28. Since most systematic reviews were constrained to working 
within EBDs only, what those studies measured was a fraction of language bias – the difference 
between English and non-English trials indexed in EBDs. The effect of language bias cannot be 
comprehensively evaluated unless non-English trials, especially the ones not indexed in EBDs, 
are included and evaluated. 
Indexing Bias 
As the primary source for systematic reviewers, EBDs may index some non-English literature 
but indeed they vary in the amount and scope. The Cochrane Handbook for Systematic reviews 
and the United States Institute of Medicine Guidelines for Systematic Reviews have 
recommended including non-English literature indexed in EBDs 1,29. Including non-English trials 
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indexed in EBDs may not eliminate the effect of language bias but could reduce it to the scope 
of indexing bias.  
To date EBDs do not represent the Chinese literature. This is problematic because an ongoing 
study shows more than 10,000 clinical trials have been published out of China in 2016 26. 
However, Embase only indexes 80 Chinese journals 7.  
While we did not simulate actual systematic reviews it appears plausible that, due to language 
and indexing bias, drug interventions might appear more positive than they are when existing 
evidence is synthesized, for example in systematic reviews.  
How to Eliminate the Effect of Language Bias Regarding CS-RCTs 
The effect of language bias regarding CS-RCTs might be eliminated if reviews comprehensively 
searched CBDs, or if major EBDs would index all Chinese literature, or if all CS-RCTs would be 
appropriately registered with results. There are, however, layers of complexity that warrant 
appreciation. There has been a discussion over whether scientists should search CBDs when 
conducting systematic reviews 8,30. Our study tipped the scales in this proposition's direction: 
including Chinese literature may reduce bias and shrink confidence intervals of the estimates. 
Currently the Cochrane Handbook for Systematic Reviews of Interventions only recommends 
searching CBD for topics related to complementary medicine or Chinese medicine 1, but our 
results suggest that it might be prudent to expand recommendations to studies on drug 
interventions as well.  
The reporting quality of Chinese CS-RCTs was low 6,31,32, which some may argue is a reason to 
not use Chinese CS-RCTs in systematic reviews. However, reporting quality may not 
completely represent the actual scientific quality 33. One study found no difference between one 
systematic review mainly using English-language trials and another one mainly using Chinese-
language trials on the same topic 8. It is the researchers' decision to include or not include those 
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trials (i.e., trials published in Chinese and/or indexed in CBDs) based on reporting quality, but it 
might be too simplistic to just ignore them. 
Limitations 
There are several limitations to our study. First, we searched seven prominent but not all 
bibliographic databases 34. Second, our search strategy relied on the information in trial 
registries, which may be inaccurate and/or incomplete 35,36. Third, less than 15% of Chinese 
articles reported registration 6,42,46, indicating CS-RCTs in trial registries may not be 
representative of all CS-RCTs in the time period addressed. At this moment it is unclear how 
much this study can be generalized to all CS-RCTs. Last, we studied language bias and 
indexing bias from the level of the entire RCT community, but we did not assess whether such 
biases might have effects on the conclusion of individual systematic reviews. Such simulation or 
empirical studies might further elucidate the extent and direction of systematic error introduced 
by language and indexing bias.  
 
Conclusion 
Our study indicates the existence of language bias and indexing bias among CS-RCTs in trial 
registries. This might threaten the validity of evidence synthesis. When synthesizing evidence, 
drug interventions might appear more favorable than in reality due to language and indexing 
bias. Removing language restrictions and actively searching CBDs may reduce the effect of 
these two biases.   
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Table 1    Coverage of Journal Articles by Bibliographic Databases 
Bibliographic 
Database 
English Article (Total=368)  Chinese Article (Total=102)  All Article (Total=470) 
Indexed  Unindexed  Indexed  Unindexed  Indexed  Unindexed 
No. %  No. %  No %  No. %  No. %  No. % 
EBD                  
    PubMed 357 97.0  11 3.0  22 21.6  80 78.4  379 80.6  91 19.4 
    Embase 364 98.9  4 1.1  24 23.5  78 76.5  388 82.6  82 17.4 
    CENTRAL 348 94.6  20 5.4  24 23.5  78 76.5  372 79.2  98 20.1 
CBD                  
    SinoMed -   -   102 100.0  0 0.0  -   -  
    CNKI -   -   66 64.7  36 35.3  -   -  
    VIP Data -   -   100 98.0  2 2.0  -   -  
    Wanfang Data -   -   101 99.0  1 1.0  -   -  
EBD: English Bibliographic Database; CENTRAL: Cochrane Controlled Register of Trials; CBD: Chinese Bibliographic Database; CNKI: China 
National Knowledge Infrastructure. 
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Table 2    Positivity of CS-RCTs by Trial Registry and Bibliographic Database 
Trial Registry 
English Article  Chinese Article  EBD  CBD 
No.  %  No.  %  No.  %  No.  % 
ChiCTR                
 Positive 180  85.3  31  14.7  186  88.2  25  11.8 
 Negative 56  59.6  38  40.4  67  71.3  27  28.7 
 Total 236  77.4  69  22.6  253  83.0  52  17.0 
English Registries                
 Positive 91  87.5  13  12.5  93  89.4  11  10.6 
 Negative 32  69.6  14  30.4  37  80.4  9  19.6 
 Total 123  82.0  27  18.0  130  86.7  20  13.3 
DCTRP                
 Positive 5  62.5  3  37.5  6  75.0  2  25.0 
 Negative 2  40.0  3  60.0  4  80.0  1  20.0 
 Total 7  53.9  6  46.1  10  76.9  3  23.1 
Total                
 Positive 276  85.5  47  14.5  285  88.2  38  11.8 
 Negative 90  62.1  55  37.9  108  74.5  37  25.5 
 Total 366  78.2  102  21.8  393  84.0  75  16.0 
 
CS-RCTs: Chinese-Sponsored Randomized Controlled Trials; ChiCTR: Chinese Clinical Trial Registry; 




Table 3    Factors Associated with Language Bias and Indexing Bias 
Factor 
Language Bias  Indexing Bias 
RR 95% CI P Value  RR 95% CI 
P 
Value 
Positivity        
 ChiCTR        
  Positive 3.92 2.20-7.00 <0.001  2.89 1.55-5.40 0.001 
  Negative* - - -  - - - 
 English Registries        
  Positive 3.22 1.34-7.78 0.009  2.19 0.82-5.82 0.117 
  Negative* - - -  - - - 
Sample Size        
 >=100 2.09 1.19-3.67 0.010  2.04 1.11-3.72 0.021 
 <100* - - -  - - - 
Number of Centers        
 Single-center 1.85 1.01-3.41 0.049  1.56 0.80-3.05 0.196 
 Multi-center* - - -  - - - 
Funding        
 Non-Industry 1.99 1.06-3.75 0.033  1.29 0.63-2.67 0.483 
 Industry* - - -  - - - 
Registration Type        
 Retrospective 1.43 0.85-2.40 0.174  1.47 0.84-2.56 0.174 
 Prospective* - - -  - - - 
Design        
 Superiority 1.17 0.36-3.80 0.797  1.30 0.35-4.78 0.698 
 Equivalence or Non-inferiority* - - -  - - - 
*Reference group 


















Registry Records Evaluated for Eligibility    N=5,084 
Eligible Records    N=903  
Excluded N=4,181 
Not on Drug N=1,766 
Not RCT N=374 
Missing Information    N=188 
Non-Chinese Sponsor or PI    N=342 
Outranged Study Period   N=939 
Phase 1 Trials    N=566 
Intra-Registry Duplicates    N=6 
• Intra-ChiCTR Duplicates    N=4 
• Intra-CT.gov Duplicates    N=2 
Eligible CS-RCTs    N=891 
Excluded    N=12 
Inter-registry Duplicates    N=12 
• ChiCTR—CT.gov Duplicates    N=4 
• CT.gov—DCTRP Duplicates    N=7 
• ChiCTR—DCTRP Duplicate     N=1 
Published CS-RCTs    N=470 
Excluded    N=421 
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Abstract 
Importance The impact of duplicate publications may be complicated by the language of 
publications. 
Objective To develop the duplicate patterns and estimate duplicate publication bias 
modified by the language of publications. 
Design  Retrospective cohort study. 
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Settings Trial registries and bibliographic databases. 
Participants RCTs conducted in mainland China between 2008 and 2014. RCTs were 
retrieved from trial registries and their Journal articles were identified from bibliographic 
databases until August 2019. Journal articles were classified as the main article (with the largest 
sample size) and duplicates (no reference to the main article). Cross-language duplicates 
referred to those published in a different language from the main articles. 
Four duplicate patterns were developed: (1) unreferenced subgroup analysis (an article fails to 
disclose itself as a subgroup analysis or reference its main article); (2) unreferenced 
republication (an article fails to disclose itself as a replicate of the main article or reference it); 
(3) unreferenced interim analysis (an article fails to disclose itself as an interim analysis or be 
referenced by its main article); (4) partial duplicate (an article fails to disclose its sharing a 
subset of participants with other articles or reference them). 
Exposure The findings of RCTs (Positive vs. Negative). 
Main Outcomes and Measures  The main outcome was an RCT having subsequent 
duplicates. We hypothesized that the main article of an RCT with positive findings was more 
likely to have subsequent duplicate(s) than those with negative findings. 
Results  Among 470 RCTs published as journal article(s), 55 (11.7%) had 75 
duplicates, of which 53 (70.7%) were cross-language duplicates. 33 (44.0%), 25 (33.3%), 15 
(20.0%), and 2 (2.7%) of 75 duplicates were unreferenced republications, unreferenced 
subgroup analyses, unreferenced interim analyses, and partial duplicates, respectively. 
When the main article of an RCT was published in Chinese, those with positive findings were 
2.48 (95%CI: 1.08 – 5.71) times more likely to have subsequent duplicates than those with 
negative findings.  
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Conclusion and Relevance Most duplicates of RCTs from China were cross-language 
duplicates and unreferenced republications of the main article. Duplicate publication bias exists 
when the main articles were published in Chinese, posing a threat to readers, journals, and 
evidence synthesis when RCTs from China are involved. 
 
Introduction 
A duplicate publication (referred to as a duplicate) 'overlaps substantially with one already 
published, without clear, visible reference to the previous publication'.1 Duplicates waste 
resources, breach copyright, undermine the integrity of research, and distort evidence if 
inadvertently included in systematic reviews.2-4  
When disseminating vital messages, secondary publications across languages can be justified, 
or even recommended, to maximize audience.1 Such secondary publications should 
appropriately disclose the relationship to the main publication to avoid being treated as an 
independent study, i.e., a duplicate.1 
Duplicates are prevalent in the health-related literature;5-10 however, it remains challenging for 
readers, editors and meta-analysts to detect duplicates, especially when the authorship, design, 
and results of duplicates deviate from the main publication.11 Moreover, duplicates may be 
concealed by language barriers thereby becoming even more challenging to be discovered. For 
example, it is not expected for English-speaking peer reviewers and editors to detect a duplicate 
originating from a non-English main publication. 
Few studies have been dedicated to assessing the interaction between duplicates and 
publication language. It is unclear how often the cross-language duplicates occur or what role 
language plays in producing duplicates and subsequently biasing evidence syntheses. In our 
study we selected RCTs from mainland China as an example, because there are several factors 
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which facilitate our study: (1) the biomedical research community is witnessing a proliferation of 
RCTs in China;12,13 (2) most Chinese literature is not indexed in English bibliographic 
databases, while a shift towards publishing RCTs from China in English has not been 
observed;14,15 (3) the coverage of the Chinese literature by English bibliographic databases has 
been gradually increasing;16,17 and (4) the Chinese literature and bibliographic databases have 
been increasingly recognized by the evidence synthesis community.18 The aims of this study 
were to estimate prevalence and detect patterns of duplicates among RCTs from mainland 
China, and to evaluate the existence of duplicate publication bias with a focus on the interaction 
between duplication and language. 
 
Methods 
In this study, we retrieved eligible RCTs from trial registries, identified the corresponding journal 
articles from bibliographic databases, developed patterns and evaluated bias regarding 
duplicate publications. We followed the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) reporting guideline.19 The study was not subject to institutional review 
board approval because all the data were open-source and no participant was involved. 
Identify Eligible RCTs from Trial Registries and Bibliographic Databases 
Our study sample comprised of RCTs sponsored by organizations located in mainland China. 
The process to retrieve registration records from trial registries and identify corresponding 
journal articles from bibliographic databases has been described previously.20 Eligible RCT 
were defined as those that evaluated the efficacy and/or safety of drugs and were conducted 
between January 1, 2008 and December 31, 2014. A substance was considered a drug if 
regulated by the United States Food and Drug Administration and/or the European Medicine 
Agency. We excluded bioequivalence studies, pharmacokinetics studies, and RCTs with 
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missing information on eligibility of participants, study period, experimental drug(s), principal 
investigators, or sponsor. 
Only journal articles originating from eligible RCTs were included. The search strategy and 
terms updated from previous studies,21-23 list of bibliographic databases,24 and criteria to match 
journal articles with registry records are described in Supplements 1-4. Two authors (YJ and 
DH) independently searched bibliographic databases and identified matching PDFs of eligible 
RCTs. Discrepancies were discussed and resolved with a third author (JW). 
Identify the Main Article and Duplicates 
All the journal articles produced from one RCT formed a cluster.11 We defined the main article 
as the one with the largest sample size and the longest follow-up. If multiple articles existed with 
the same sample size and follow-up period, the one submitted earliest to a journal was 
considered the main article. A duplicate was operationally defined as an article that had at least 
one duplicated outcome but failed to disclose its relationship with, or reference to, or be 
referenced by the main article. 
In this study we focused on duplicates that might distort evidence, so duplicates were 
considered only in terms of outcomes regardless of the background, method, or discussion 
section of the article. We dissected outcomes into five elements, i.e., domain (e.g., systolic 
blood pressure), specific measurement (e.g., a device at sitting position), specific metric (e.g., 
change from baseline), the method of aggregation (e.g., mean/median), and time-points.25 An 
outcome was considered duplicated if it had the identical domain, specific measurement, and 
time-point with an outcome in the main article, regardless of the specific metric or the method of 
aggregation. For example, an article was considered a duplicate if it reported the mean of 
systolic blood pressure while the main article reported the median, as long as the measurement 




We developed four patterns of duplicates based on the progress of recruitment and follow-up of 
individual RCTs: (1) unreferenced subgroup analyses; (2) unreferenced republications; (3) 
unreferenced interim analyses; and (4) partial duplicates.  
Unreferenced Subgroup Analysis    This is defined as an article that fails to disclose itself as 
a subgroup analysis or reference its main article. Unreferenced subgroup analyses are 
published following the main articles. We defined three sub-patterns: (i) subgroup of recruiting 
centers, in which only participants from a subset of recruiting centers are included; (ii) subgroup 
of treatment groups, in which only participants from a subset of treatment groups are included; 
and (iii) subgroup of participants' characteristics, in which only participants with specific 
characteristics are included, for instance, the main article is on heart failure while the 
unreferenced subgroup analysis is on heart failure and diabetes.  
Unreferenced Republication    This is defined as an article that fails to disclose itself as a 
replicate of the main article, i.e., reports identical participants and follow-up period with the main 
article, or references the main article. Unreferenced republications are published following the 
main articles. 
Unreferenced Interim Analysis    This is defined as an article that fails to disclose itself as an 
interim analysis or be referenced by the main article published subsequently. We defined three 
sub-patterns: (i) interim report of recruitment, which reports an interim analysis on a subset of 
participants before recruitment is complete, usually the participants recruited in the early stage; 
(ii) interim report of follow-up, which reports an interim analysis on all the participants but before 
the follow-up is complete, usually on short-term outcomes; and (iii) interim report of both 
recruitment and follow-up, i.e., an interim analysis on a subset of participants before recruitment 
and follow-up are complete. 
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Partial Duplicate    A partial duplicate is an article that contains a portion of unique participants 
while sharing a portion of participants, e.g., a subset of recruiting centers or recruiting period, 
with a main article which is not referenced. Partial duplicates are published following the main 
articles. 
We also classified duplicates into cross-language duplicates and same-language duplicates. 
Cross-language duplicates refer to those published in a different language from the main 
articles, i.e., the main article is published in Chinese and the duplicate in English, or vice versa. 
Same-language duplicates refer to those published in the same language as the main articles, 
i.e., the main article and the duplicate are both published in Chinese or English. 
Duplicate Publication Bias 
We hypothesized that a main article with positive findings was more likely to have subsequent 
duplicate(s) than those with negative findings.  
Exposure    An article was classified as positive or negative according to its primary outcome. If 
multiple primary outcomes were reported, the first one reported in the results section was 
selected. If no primary outcome was defined, we selected the primary outcome based on the 
following hierarchical order: the first outcome used in the sample size calculation, the first 
outcome defined in the study objectives, or the first outcome reported in the results section.26 
When the primary outcome was measured at multiple time points, we considered the last time 
point in the analysis. 
We defined positive findings as favoring the study hypothesis with statistical significance. For 
example, a superiority trial was positive when the experimental drug was significantly superior 
over the comparator. We defined negative findings as not statistically significant or contradictory 
to the study hypothesis.  
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Outcome    A main article had duplicate(s) when at least one unreferenced subgroup analysis, 
one unreferenced republication, or one partial duplicate was identified in the same cluster.  
Effect Modifier We hypothesized that the language of the main article was a possible 
effect modifier, i.e., the association between the study findings and having subsequent 
duplicate(s) might vary by the language of the main article. 
Measurements of Associations    Duplicate Publication Bias was estimated by the relative risk 
(RR). An RR larger than one indicates that a main article was more likely to have subsequent 
duplicate(s) when the findings were positive. RRs were estimated using log binomial models 
with four covariates: language of the first journal article (Chinese versus English), sample size 
(<100 versus ≥100), funding source (industry versus non-industry), and number of recruiting 
centers (single versus multiple).27-29 An RCT was defined as funded by industry if at least one 
funder was from industry. An interaction term was included in the model to account for the 
language of the main article as an effect modifier. Statistical significance was defined as a p 
value less than 0.05 for the main effect and 0.1 for interactions. SAS® 9.4 was used for data 
management and analysis. 
 
Results 
In total, 891 eligible RCTs were identified from five registries. Through August 2019, 470 trial 
results had been published as journal article(s). 75 duplicates were identified from 55 RCTs 
(11.7%), of which 47 (63.5%) were in Chinese (Figure 1). The majority (45/55, 81.8%) of 
clusters only had 1 duplicate, while 10 had more than one duplicates (range: 1 to 6). 
53 (70.7%) duplicates crossed language, including 20 (26.7%) in English (while the main article 
was in Chinese) and 33 (44.0%) in Chinese (while the main article was in English). 22 (29.3%) 
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duplicates were in the same language as the main articles, including 15 (20.0%) in Chinese and 
7 (9.3%) in English. 
The characteristics of RCTs having duplicate(s) were generally similar to RCTs without 
duplicates. Among 55 RCTs having duplicate(s), 10 (18.8%) were sponsored by industry (as 
opposed to non-industry), 25 (47.2%) recruited fewer than 100 participants, 13 (24.5%) were 
conducted at one recruiting center only, and 38 (71.7%) reported positive findings. Among 415 
RCTs without duplicates, 83 (19.9%) were sponsored by industry, 162 (38.9%) recruited fewer 
than 100 participants, and 135 (32.4%) were conducted at one recruiting center. The nature of 
findings was not determined for 2 RCTs without duplicates in which no between-group 
comparison was reported and were excluded from the analysis on bias. In the remaining 413 
RCTs without duplicates, 292 (70.4%) reported positive findings. 
Duplicate Patterns 
The duplicate patterns are shown in Table 1. 
The most prevalent pattern was unreferenced republication. Thirty-three (44.0%) of 75 
duplicates fit this pattern, including all 4,044 participants reported in the main articles. Twenty-
five (75.8%) duplicates crossed language, including 15 (45.5%) in English (while the main article 
was in Chinese) and 10 (30.3%) in Chinese (while the main article was in English). 
Twenty-five (33.3%) duplicates were unreferenced subgroup analyses, of which 7 (28.0%) were 
subgroups of centers, 4 (16.0%) were subgroups of treatment groups, 4 (16.0%) were 
subgroups of participants' characteristics, 2 (8.0%) were subgroups of both centers and 
participants' characteristics, and 8 (32%) were unclear owing to lack of sufficient information. 
The 25 unreferenced subgroup analyses included 2,193 (66.6%) of 3,295 participants reported 
in the main articles. Fifteen (60.0%) duplicates crossed language, including 11 (44.0%) in 
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Chinese (while the main article was in English) and 4 (16.0%) in English (while the main article 
was in Chinese). 
Fifteen (20.0%) of 75 duplicates were unreferenced interim analyses, of which 13 were analyses 
of recruitment, 2 were analyses of follow-up, and 1 was an analysis of a mixture of recruitment 
and follow-up. The 15 unreferenced interim analyses included 1,125 (45.6%) of 2,468 
participants reported in the main articles. Twelve (80.0%) duplicates crossed language, all of 
which were in Chinese (while the main articles were in English). 
There were 2 partial duplicates (2.7%), of which one crossed language and the other was the 
same language as the main article. 
Duplicate Publication Bias 
We did not find evidence supporting the language of the main article as an effect modifier 
(χ2=1.60, P=0.21). After adjusting for covariates, when published in Chinese, the main articles 
with positive findings were 2.48 (95% CI: 1.08 to 5.71) times more likely to have subsequent 
duplicate(s) than RCTs with negative findings. There was no evidence supporting a similar bias 
when the main articles were published in English (RR=0.99, 95%CI: 0.31 to 3.13). The main 
articles published in Chinese were 7.68 (95%CI: 3.72 to 15.87) times more likely to have 
subsequent duplicate(s) than those published in English. None of other covariates reached 
statistical significance (Table 2). 
 
Discussion 
Our study revealed that duplicates continued to haunt the medical literature, especially those 
published in different languages which were challenging to detect. It is unclear how likely the 
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occurrence of duplicates is due to lack of awareness: it is possible that some researchers may 
produce duplicates unaware of the inappropriateness, while others may do so deliberately.   
Aside from research integrity and legal considerations, the presence of duplicates carries the 
potential to distort evidence by double-counting trials results in systematic reviews.3,4 Currently 
there is a deep gap between English and Chinese literature, i.e., most Chinese RCTs are 
published in Chinese and only indexed in Chinese bibliographic databases, and very few 
Chinese journals are covered by major English bibliographic databases.14,16 Meanwhile, 
systematic reviews, which should bridge the language gap, nearly always fail to search Chinese 
bibliographic databases and subsequently do not include RCTs published in Chinese.30 Under 
such circumstances, the cross-language duplicates, especially when the main articles are 
published in Chinese while the duplicates are in English journals, raise serious concerns. An 
English duplicate is more accessible to most reviewers than the Chinese main article, but it is 
possible that the duplicate is only a subset of participants with positive findings or with larger 
effect sizes. Although this type was only present in 5% of all duplicates in our sample, reviewers 
should be vigilant considering the sheer quantity of RCTs being conducted in China. 
On the other hand, simply excluding the Chinese literature may lead to other negative 
consequences, for example, missing relevant RCTs may lead to narrower confidence intervals 
than if these RCTs were not missing.14 Moreover, we observed a language bias among RCTs, 
which means positive findings stand a higher chance to then be published in English than 
negative findings; excluding the Chinese literature may increase the risk of overestimating 
treatment effects.20 Meanwhile, the coverage of Chinese journals by major English bibliographic 
databases has been increasing gradually, while more and more systematic reviews on some 
specific topics have recently started to include Chinese bibliographic databases to reduce 
bias.18 The trend of increasing overlap between English and Chinese literature exemplifies the 
possibility of distorting evidence by including duplicates, because all the patterns could possibly 
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be included in systematic reviews. Theoretically, unreferenced republications would be the 
greatest threat as they carry the weight of entire trials. However, as their study participants and 
results are typically identical to the main articles, it may not be difficult for a meticulous reviewer 
to detect them. On the other hand, unreferenced subgroup analyses and unreferenced interim 
analyses can differ tremendously from the main articles, which may be more challenging for 
reviewers and editors to detect. 
Although we did not find evidence that the language of the main article was an effect modifier, 
the association between the nature of findings of the main articles and the possibility of having 
subsequent duplicate(s) was only statistically significant when they were published in Chinese, 
a phenomenon that might be explained by the desire to publish in English journals with higher 
impact factors and reputation. This also implies that the language of publication may have the 
potential to modify the duplicate publication bias, and that the negative result in our study may 
be owing to a small sample size. 
In our study, we could not determine the duplication status of some articles owing to a lack of 
key information or inconsistencies between trial registries and published journal articles.31-33 
Improving the data quality of trial registries and the reporting quality of journal articles could 
enable reviewers to capture duplicates in a more efficient manner.  
There are several limitations of this study. First, the sample size of RCTs in the study was 
limited. A larger sample size would enable us to better quantify the effect of language on bias. 
Second, we applied strict rules with high specificity to identify duplicates at the cost of sensitivity 
and consequently we may have missed some duplicates – especially those which are 
substantially inconsistent with the main articles, or lacking information for classification. Thus, 
the actual prevalence of duplicates among RCTs may be much higher than our estimate and 
there may be patterns of duplication that we failed to identify. Third, because less than 15% of 
RCTs were registered, RCTs in trial registries may not be representative of all RCTs.34 We are 
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thus reluctant to extrapolate our conclusion to all the RCTs. Fourth, although we found evidence 
supporting the existence of duplicate publication bias, further study is needed to determine how 
much duplicates, especially cross-language duplicates, affect the conclusions of individual 
systematic reviews. Finally, we only selected Chinese RCTs as our study sample and the 
duplicate prevalence, patterns, and bias may vary in other languages. For example, in 
Germany, there has been a major trend towards publishing clinical trials in English;15 as a result, 
cross-language duplicates may subsequently disappear. Nonetheless, we believe our study is 
informative for future research on RCTs in other languages. 
 
Conclusion 
Most duplicates were cross-language duplicates and unreferenced republications of the main 
article. Duplicate publication bias exists when the main articles were published in Chinese while 
the duplicates in English, posing a threat to readers, journals, and evidence synthesis when 




Table 1    Patterns of Duplicates 
Pattern Sub-Pattern Cross Language Same Language Total English* Chinese** Total Chinese English Total 
Unreferenced Interim 
Analysis 
Interim Reported of Recruitment 0 9 9 2 1 3 12 
Interim Reported of Follow-up 0 2 2 0 0 0 2 
Interim Reported of Recruitment 
and Follow-up 0 1 1 0 0 0 
1 
Total 0 12 12 2 1 3 15 (20.0%) 
         
Unreferenced 
Republication - 15 10 25 6 2 8 
33 
(44.0%) 
         
Unreferenced 
Subgroup Analysis 
Subgroup of Centers 2 1 3 4 0 4 7 
Subgroup of Treatment Groups 0 3 3 1 0 1 4 
Subgroup of Participants' 
Characteristics 0 2 2 0 2 2 
4 
Subgroup of Centers and 
Participants' Characteristics 0 2 2 0 0 0 
2 
Unclear 2 3 5 2 1 3 8 
Total 4 11 15 7 3 10 25 (33.3%) 
         
Partial Duplicate - 1 0 1 0 1 1 2 (2.7%) 
         











*Duplicate are published in English, while main articles are published in Chinese. 
*Duplicate are published in Chinese, while main articles are published in English. 
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Table 2    Factors Associated with Duplicate Publication Bias 
Factor Comparison RR 95% CI P Values Lower Limit Upper Limit 
Nature of Findings of the Main Article       
 the Main Article is in Chinese Positive vs. Negative 2.48 1.08 5.71 0.03 
 the Main Article is in English Positive vs. Negative 0.99 0.31 3.13 0.99 
      
Language of the Main Article Chinese vs. English 8.03 3.91 16.46 <0.01 
      
Sample Size ⩾100 vs. <100 1.07 0.54 2.13 0.85 
      
Funding Non-Industry vs. Industry 1.39 0.59 3.26 0.45 
      
Number of Recruiting Centers Single Center vs. Multiple Centers 1.58 0.71 3.50 0.26 
RR: Relative Risk 
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Figure 1    Selection of RCTs with Duplicate(s)  
Registry Records Evaluated for Eligibility    N=5084 
Eligible Records    N=903  
Excluded N=4181 
Not Eligible    N=3987 
Missing Information    N=188 
Intra-Registry Duplicated Registers    N=6 
Eligible RCTs    N=891 
Excluded    N=12 
Inter-registry Duplicated Registers    N=12 
• ChiCTR—CT.gov Duplicated Registers    N=4 
• CT.gov—DCTRP Duplicated Registers    N=7 
• ChiCTR—DCTRP Duplicated Registers    N=1 
Published RCTs    N=470 
Excluded    N=421 
Unpublished RCTs   N=421 
Published RCTs with Duplicate(s)    N=55 
Excluded    N=421 





Summary of Findings and Implications 
This dissertation was among the first attempts to evaluate reporting bias among RCTs from 
mainland China. Chapter 1 was the first study to evaluate the switching of registered primary 
outcomes. Chapter 2 was the first study to evaluate language bias between Chinese and 
English literature and indexing bias between English and Chinese bibliographic databases. 
Chapter 3 was the first study to evaluate duplicate publication bias. We found evidence 
supporting all three types of reporting bias. 
Findings of Chapter 1 
Chapter 1 focused on the switching of pre-specified primary outcomes of RCTs. We found 
evidence supporting that registered primary outcomes with negative findings were more likely to 
be downgraded to secondary outcomes in the subsequent journal articles than those with 
positive findings. This association between the switching of primary outcomes and the nature of 
findings was consistent across trial registries (bilingual registry vs. English registries), but was 
modified by the timing of registration (prospectively registered vs. retrospectively registered 
before trial completion vs. retrospectively registered after trial completion). The strongest 
association was observed when RCTs were retrospectively registered before trial completion. 
Implications of Chapter 1 
The switching of primary outcomes would not distort evidence synthesized by systematic 
reviews should all outcomes are appropriately disclosed. However, researchers may selectively 
report outcomes with positive findings, a phenomenon termed outcome reporting bias;35 the pre-
specified primary outcomes with negative findings are at risk to be downgraded to secondary 
outcomes and omitted from publications, which would result in overestimated evidence. 
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On the other hand, the switching of primary outcomes may inappropriately underline positive 
findings and bias the interpretation of individual RCTs. Primary outcomes of clinical trials are 
carefully selected at the design stage which are deemed most important and relevant to the 
research question, of which the probability of false positivity or false negativity are controlled by 
appropriate sample size and statistical testing.36 On the contrary, secondary outcomes with 
positive findings bear higher probability of false positivity.37 Downgrading a negative pre-
specified primary outcome to be secondary in the publication while upgrading a positive pre-
specified secondary outcome to be primary in the publication grants the secondary outcome the 
equivalent importance and credibility of a primary outcome. The interpretation of the RCT based 
on the newly introduced primary outcome, which is very likely to be false positive, is at high risk 
of bias. 
The switching of primary outcome can flip the interpretation of an RCT from 'failure' to 'success' 
among health care providers, researchers, and journal editors. When systematic reviews are not 
available, the evaluation of health interventions by stakeholders may rely on individual RCTs. It 
is possible to adopt a health intervention by stakeholders that is of little therapeutic value to 
patients when primary outcome switching occurs. In addition, switching of pre-specified primary 
outcomes among pivotal trials may lead to marketing license of health interventions granted by 
legal authorities that is of little therapeutic value to patients. 
Recommendations of Chapter 1 
The switching of primary outcomes can be detected by comparing publications with protocols, 
which unfortunately are not always available to the public. With key items of protocols, trial 
registries remain a powerful alternative for researchers to detect and evaluate the switching of 
primary outcomes. However, to date less than 15% of RCTs from mainland China have been 
registered, restricting the role of trial registries.38 This chapter advocates prospective registration 
of all RCTs from mainland China to facilitate detection of primary outcome switching, the first 
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step to reduce its occurrence in the future. In addition, reviewers of manuscripts of RCTs are 
recommended to compare the manuscripts with registries to detect any switching of primary 
outcomes; authors of manuscripts should be required to explain any identified discrepancy. 
Findings of Chapter 2 
Chapter 2 focused on the language bias and indexing bias. We found evidence supporting that 
RCTs with positive findings were more likely to be published in English and indexed in English 
bibliographic databases than those with negative findings. The direction of associations 
(between the nature of findings and the language of the subsequent journal articles, between 
the nature of findings and the language of bibliographic databases where the journal articles 
were indexed) were consistent across registries, although the magnitude of associations were 
larger among RCTs retrieved from bilingual registry than those from English registries. 
Implications of Chapter 2 
English-speaking investigators, who fail to consider Chinese literature when searching English 
bibliographic databases, are more likely to include positive findings in systematic reviews to 
overestimate treatment effect when research from mainland China is involved. Removing 
language restrictions to include Chinese literature indexed in English bibliographic databases 
can only capture a small fraction of Chinese journals, therefore, to reduce the impact of 
language bias to a very limited extent owing to indexing bias. Only by searching Chinese 
bibliographic databases to include all Chinese literature can researchers further eliminate the 
impact of both language bias and indexing bias on systematic reviews. 
Language bias and indexing bias unproportionally expose positive findings to researchers 
synthesizing evidence, which may lead to overestimate of treatment effect. Traditionally 
Chinese literature has been overlooked by researchers in English-speaking countries except for 
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certain treatments originated from China.39 This chapter rings the alarm for possible bias 
introduced into systematic reviews by overlooking Chinese literature. 
Recommendations of Chapter 2 
There are several ways to possibly reduce the impact of language bias and/or indexing bias. 
First, there has been a prolonged discussion about the necessity of including Chinese 
bibliographic databases in systematic reviews. The reporting and conducting quality of RCTs in 
Chinese bibliographic databases is allegedly lower than their English counterparts.40 Some 
English-speaking researchers argue it may not be worth the time and resources to 
comprehensively search bibliographic databases in another language. Although it is still at the 
discretion of individual researchers to value Chinese bibliographic databases, Chapter 2 tips the 
balance towards including them in systematic reviews. 
Second, the comprehensive registration of RCTs from mainland China can help researchers 
identify all RCTs regardless of where they are published or indexed. Targeting the RCTs from 
registries may reduce the workload of researchers to a substantial extent. Again, it is urgent to 
improve the registration of RCTs from mainland China. 
Third, it is possible to reduce the impact of indexing bias by increasing the coverage of Chinese 
journals by major English bibliographic databases, such as PubMed and Embase, therefore 
researchers would be able to identify all relevant Chinese literature by removing language 
restriction when search English bibliographic databases. However, it is challenging to include all 
Chinese journals owing to their suboptimal quality.41  
Findings of Chapter 3 
Chapter 3 focused on the patterns of duplicates and duplicate publication bias. We found 
evidence supporting that more than 10% of RCTs from mainland China had at least one 
duplicate. The duplicates could be classified as four patterns: (1) unreferenced subgroup 
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analysis (an article that reports a subgroup analysis of an RCTs but fails to reference its main 
article.); (2) unreferenced republication of the main article (an article that reports all the 
participants with complete follow-up in an RCT but fails to reference its main article); (3) 
unreferenced interim analysis (an article that reports an interim analysis of an RCT but is not 
referenced by the main article published subsequently); and (4) partial duplicate (shared a 
subset of participants with other articles but no reference). Most duplicates were unreferenced 
republication of the main articles and published in a different language from the main articles. 
When the main articles were published in Chinese, RCTs with positive findings were more likely 
to have subsequent duplicates than those with negative findings. This duplicate publication bias 
was not supported when the main articles were published in English. 
Implications of Chapter 3 
Duplicates may be challenging to detect, especially when the authorship, design and results of 
duplicates are inconsistent with the main articles. In non-English speaking countries, the 
occurrence of duplicates may be further complicated by the language barrier. It is challenging 
for English-speaking researchers, journal editors, and reviewers to detect an English duplicate 
when the main article is published in Chinese. 
Producing duplicates constitutes plagiarism and violates copyright. The resume of researchers 
may be inappropriately enriched by including duplicates. Moreover, Duplicate publication bias 
may result in more positive findings from duplicates being inadvertently included in systematic 
reviews to overestimate treatment effects. Although we reported four patterns of duplicates to 
shed a light on how duplicates occurred, it is noteworthy that there may be more patterns that 
are too complicated or obscure to be detected by researchers solely based on publications.11 
Recommendations of Chapter 3 
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We recommend academic journals to update the instruction for authors to highlight that 
publishing original data secondarily in another language without referencing the primary 
publication is not acceptable. Researchers conducting systematic reviews should be alerted to 
the possible existence of cross-language duplicates and actively search for them if necessary, 
especially for the patterns detected in this dissertation.  
The importance of trial registration is highlighted again by Chapter 3. It would be much easier 
for researchers to detect duplicates if all trial-related publications provide registration identity, an 
action that should be taken by all academic journals. In addition, intentionally produced 
duplicates are considered scientific misconduct.42 By developing appropriate regulations, the 
government may establish watchdog to actively monitor and take legal actions against possible 
duplicates. Such legal actions may also be considered by academic journal of which copyright is 
violated. 
 
All three types of reporting bias favored positive findings, posing a risk of overestimating 
treatment effects. Researchers synthesizing evidence, journal editors, and policy makers should 
be aware of those biases. Imminent actions, such as strengthening trial registration, including 
Chinese literature and Chinese bibliographic databases in reviews, and updating the author 
instructions of journals should be considered in the future. 
 
Future Directions 
We suggest eight pathways for future studies. 
First, we only evaluated three types of reporting bias among RCTs from mainland China. More 
studies are needed to evaluate other types of reporting bias, such as publication bias, outcome 
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reporting bias, time lag time, citation bias, etc. For example, there have been concerns over the 
disproportionate abundance of positive findings from RCTs from mainland China. One possible 
explanation may be an alarming publication bias, therefore positive findings are more likely to 
be published. Such concerns warrant future research. 
Second, we only included RCTs from trial registries. Because only a few RCTs from mainland 
China are registered, it is unclear whether the selected RCTs in this dissertation can be 
representative of all RCTs from mainland China, therefore any direct extrapolation of the 
conclusions to other settings may not be appropriate. More studies on representative samples 
are recommended to assess reporting bias in the future, for example, RCTs approved by ethics 
committees of research hospitals or funded by government agencies. 
Third, we did not assess the impact of the reporting bias, including language bias and duplicate 
publication bias, on individual systematic reviews. Although we found evidence supporting the 
existence of reporting bias on the level of the clinical trial community, it was unclear whether 
and how much reporting bias would distort evidence synthesized by individual systematic 
reviews. For example, for specific systematic reviews on research topics that did not involve 
research from mainland China, language bias should not be a concern. How many and how 
much of systematic reviews could be affected by those types of reporting bias remain unclear 
and warrant future research.  
Fourth, the sample size of this dissertation was limited. It was not feasible to evaluate the trend 
of reporting bias over time. For example, are those types of reporting bias changing over time? 
Is the prevalence of duplicates increasing? Are there new patterns of duplicates? It is necessary 
to trace the change of reporting bias in the future. 
Fifth, we only evaluated one or two possible effect modifiers in each chapter. There may be 
more interesting confounders or effect modifiers to explore, which warrant a larger sample size. 
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For example, some RCTs having more than three registered primary outcomes may be different 
from those with a single registered primary outcome in terms of primary outcome switching; 
RCTs published in Chinese are less likely to specify primary outcomes than those published in 
English, which may have impact on reporting bias. 
Sixth, the structure and function of Chinese bibliographic databases should be appropriately 
upgraded. The major Chinese bibliographic databases are not use-friendly and can only support 
systematic reviews with limited scope. For example, most Chinese bibliographic databases only 
allow users to export 50 records at one time, which could be rather cumbersome for researchers 
conducting systematic reviews covering thousands of records. Another major challenge is that 
none of the Chinese bibliographic databases provide legitimate control vocabulary. Although the 
Medical Subject Headings (MeSH) developed by the National Library of Medicine to index 
literature has been translated to Chinese, to date most Chinese literature has not been 
appropriately indexed by the Chinese bibliographic databases and linked to the Chinese MeSH 
terms, therefore reviewers could not retrieve records correctly by searching Chinese MeSH 
terms. 
Seventh, although we recommended including Chinese literature and Chinese bibliographic 
databases in systematic reviews, to date there has been no RCT filter available on Chinese 
literature. It is urgent to develop RCT filters with varying levels of sensitivity and specificity (e.g., 
maximum sensitivity, balanced sensitivity and specificity, and maximum specificity) to facilitate 
retrieval of RCTs from Chinese bibliographic databases. 
Eighth, the impact of reporting bias may vary substantially across countries. In this dissertation 
we only evaluated three types of reporting bias among RCTs from mainland China. Owing to 
different academic systems and cultures, the significance of reporting bias is expected to be 
varying. It is necessary to evaluate reporting bias among RCTs from other non-English speaking 





This dissertation found evidence supporting three types of reporting bias among RCTs from 
China, including primary outcome switching, language bias/indexing bias, and duplicate 
publication bias. Registered primary outcomes with negative findings are more likely to be 
downgraded to secondary outcomes in the subsequent journal articles than those with positive 
findings; RCTs with positive findings are more likely to be published in English and indexed in 
English bibliographic databases; RCTs with positive findings are more likely to have subsequent 
duplicates than those with negative findings. Future research is needed to explore more types of 






Appendix A: Supplementary Materials for Chapter 1 
Supplement 1    Search Strategies 
Strategy 1 Single-Center and Multi-Center RCTs Registration Number 
Strategy 2 Single-Center and Multi-Center RCTs PI's Name AND PI's Affiliation AND (Disease OR Drug) AND Study End Date 
Strategy 3 Multi-Center RCTs Recruitment Facilities AND Disease AND Drug AND Study End Date 
PI: Principle Investigator; RCT: Randomized Controlled Trials. 
 
Supplement 2    Search Terms 
Database Identifier Source of Subjects Source of Keywords 
English 
Disease MeSH Emtree 
Registry records 
PubMed entry terms 
Embase synonyms 
Drug MeSH Emtree 
Registry records 
PubMed entry terms 
Embase synonyms 
    
Chinese 
Disease MeSH (Chinese version) 
Registry records 
ICD-10 (Chinese version) 
ICD-9 (Chinese version) 
Three doctors from PUMC 
Drug MeSH (Chinese version) 
Registry records 
China FDA website for drug trade names and compound names 
Three pharmacists from PUMC 
MeSH: Medical Subject Headings; Emtree: Embase Subject Headings; ICD-9: The International Classification of Diseases, Ninth Revision; ICD-




Supplement 3    Method to Match Journal Articles with Registry Records 
Criteria 
Similar Eligibility Criteria & Interventions, Same Registration Number 
Similar Eligibility Criteria & Interventions, Same Ethics Committee Approval Number 
Similar Eligibility Criteria & Interventions, Same Funding Identification 
Consistent Eligible Criteria & Interventions, Similar Sample Size & Overlapped Study Period 
Consistent Eligible Criteria & Interventions, Identical Sample Size 




















Supplement Table 4    Factors Associated with Discrepancy between Registered and Published Primary Outcomes: 
Sensitivity Analysis 1 (On Outcomes Designated as Primary in Journal Articles) 
 
Factor Level Stratum OR 95%CI P Value 
Nature of Findings Negative vs. Positive 
    
Prospective Registration 2.44 1.03 – 5.75 0.04 
Retrospective Before Trial Completion 8.29 3.06 – 22.46 <0.01 
Retrospective After Trial Completion 0.77 0.29 – 2.09 0.61 
    
ChiCTR & Prospective Registration 2.74 1.21 – 6.20 0.02 
ChiCTR & Retrospective Before Trial Completion 9.32 3.22 – 26.94 <0.01 
ChiCTR & Retrospective After Trial Completion 0.87 0.34 – 2.22 0.77 
    
English Registries & Prospective Registration 2.17 0.63 – 7.51 0.22 
English Registries & Retrospective Before Trial 
Completion 7.38 2.09 – 26.08 <0.01 
English Registries & Retrospective After Trial 
Completion 0.69 0.18 – 2.67 0.59 
      
Registry ChiCTR vs. English Registries 4.20 1.90 – 9.27 <0.01 
     
Timing of Registration 
Prospective vs.  Retrospective After Trial Completion 0.49 0.21 – 1.16 0.10 
Retrospective Before Trial Completion vs.  Retrospective After Trial 
Completion 0.52 0.23 – 1.20 0.12 
     
Sample Size >=100 vs. <100 0.64 0.30 – 1.37 0.25 
     
Funding Non-Industry vs. Industry 1.09 0.41 – 2.93 0.86 
     
Number of Recruiting Centers Single vs. Multiple 2.96 1.18 – 7.42 0.02 
Abbreviations 





Supplement Table 5   Factors Associated with Discrepancy between Registered and Published Primary Outcomes: 
Sensitivity Analysis 2 (Worst-Case Scenario) 
 
Factor Level Stratum OR 95%CI P Value 




Prospective Registration 1.20 0.58 – 2.51 0.62 
Retrospective Before Trial Completion 3.05 1.33 – 7.01 0.01 
Retrospective After Trial Completion 0.48 0.19 – 1.17 0.10 
    
ChiCTR & Prospective Registration 1.57 0.80 – 3.09 0.19 
ChiCTR & Retrospective Before Trial Completion 3.99 1.64 – 9.68 <0.01 
ChiCTR & Retrospective After Trial Completion 0.62 0.27 – 1.42 0.26 
    
English Registries & Prospective Registration 0.92 0.31 – 2.75 0.88 
English Registries & Retrospective Before Trial 
Completion 2.33 0.79 – 6.89 0.12 
English Registries & Retrospective After Trial 
Completion 0.36 0.11 – 1.24 0.11 
      
Registry ChiCTR vs. English Registries 3.74 1.89 – 7.41 <0.01 
     
Timing of Registration 
Prospective vs.  Retrospective After Trial Completion 0.47 0.22 – 1.00 0.05 
Retrospective Before Trial Completion vs.  Retrospective After Trial 
Completion 0.69 0.34 – 1.40 0.30 
     
Sample Size >=100 vs. <100 0.66 0.35 – 1.26 0.21 
     
Funding Non-Industry vs. Industry 1.53 0.65 – 3.60 0.32 
     
Number of Recruiting Centers Single vs. Multiple 1.96 0.91 – 4.23 0.09 
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Supplement Table 6   Factors Associated with Discrepancy between Registered and Published Primary Outcomes: 
Sensitivity Analysis 3 (Best-Case Scenario) 
 
 
Factor Level Stratum OR 95%CI P Value 




Prospective Registration 5.00 2.38 – 10.51 <0.01 
Retrospective Before Trial Completion 17.06 6.88 – 42.31 <0.01 
Retrospective After Trial Completion 2.18 0.92 – 5.15 0.08 
    
ChiCTR & Prospective Registration 4.66 2.29 – 9.46 <0.01 
ChiCTR & Retrospective Before Trial Completion 15.89 6.2 – 40.72 <0.01 
ChiCTR & Retrospective After Trial Completion 2.03 0.9 – 4.56 0.09 
    
English Registries & Prospective Registration 5.37 1.82 – 15.87 <0.01 
English Registries & Retrospective Before Trial Completion 18.32 5.76 – 58.25 <0.01 
English Registries & Retrospective After Trial Completion 2.34 0.72 – 7.64 0.16 
      
Registry ChiCTR vs. English Registries 3.70 1.84 – 7.42 <0.01 
     
Timing of Registration Prospective vs.  Retrospective After Trial Completion 0.54 0.25 – 1.15 0.11 Retrospective Before Trial Completion vs.  Retrospective After Trial Completion 0.50 0.24 – 1.04 0.06 
     
Sample Size >=100 vs. <100 0.65 0.33 – 1.28 0.21 
     
Funding Non-Industry vs. Industry 1.38 0.57 – 3.39 0.48 
     
Number of Recruiting 
Centers Single vs. Multiple 1.91 0.85 – 4.3 0.12 
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Appendix B: Supplementary Materials for Chapter 2 
 
Supplement 1    Search Strategies 
Strategy 1 Single-Center and Multi-Center CS-RCTs Registration Number 
Strategy 2 Single-Center and Multi-Center CS-RCTs PI's Name AND PI's Affiliation AND (Disease OR Drug) AND Study End Date 
Strategy 3 Multi-Center CS-RCTs Recruitment Facilities AND Disease AND Drug AND Study End Date 
PI: Principle Investigator; CS-RCT: Chinese-Sponsored Randomized Controlled Trials. 
 
Supplement 2    Search Terms 
Database Identifier Source of Subjects Source of Keywords 
English 
Disease MeSH Emtree 
Registry records 
PubMed entry terms 
Embase synonyms 
   
Drug MeSH Emtree 
Registry records 
PubMed entry terms 
Embase synonyms 
    
Chinese 
Disease MeSH (Chinese version) 
Registry records 
ICD-10 (Chinese version) 
ICD-9 (Chinese version) 
Three doctors from PUMC 
   
Drug MeSH (Chinese version) 
Registry records 
China FDA website for drug trade names and compound names 
Three pharmacists from PUMC 
MeSH: Medical Subject Headings; Emtree: Embase Subject Headings; ICD-9: The International Classification of Diseases, Ninth Revision; ICD-











No. % No. % No. % 
Confirmed Matches       
 Similar Eligibility Criteria & Interventions, Same Registration Number 311 84.5 20 19.6 331 70.4 
 Similar Eligibility Criteria & Interventions, Same Ethics Committee Approval Number 1 0.3 8 7.8 9 1.9 
 Similar Eligibility Criteria & Interventions, Same Funding Identification 2 0.5 1 1.0 3 0.6 
 Consistent Eligible Criteria & Interventions, Similar Sample Size & Overlapped Study Period 38 10.3 40 39.2 78 16.6 
 Consistent Eligible Criteria & Interventions, Identical Sample Size 7 1.9 3 2.9 10 2.1 
 Consistent Eligible Criteria & Interventions, Identical Study Period 1 0.3 0 0.0 1 0.2 
 Total 360 97.8 72 70.6 432 91.9 
Probable Matches       
 Consistent Eligibility Criteria & Interventions Similar Sample Size 7 1.9 16 15.7 23 4.9 
 Consistent Eligibility Criteria & Interventions Overlapped Study Period 1 0.3 14 13.7 15 3.2 
 Total 8 2.2 30 27.4 38 8.1 







Supplement 4   Characteristics of Published CS-RCTs by Language of Journal Articles 
 
Category 
English Articles  Chinese Articles  Total 
No.  %  No.  %  No.  % 
Positivity            
 Positive 276  75.41  47  46.1  323  69.0 
 Negative 90  24.59  55  53.9  145  31.0 
Sample Size            
 >=100 230  62.5  56  54.9  286  60.9 
 <100 138  37.5  46  45.1  184  39.1 
Number of Centers            
 Multi-center 108  29.35  40  39.2  148  31.5 
 Single-center 260  70.65  62  60.8  322  69.5 
Funding            
 Industry 63  17.12  30  29.4  93  19.8 
 Non-Industry 305  82.88  72  70.6  377  80.2 
Registration Type            
 Prospective 115  31.25  40  39.2  155  33.0 
 Retrospective 253  68.75  62  60.8  315  67.0 
Design            
 Superiority 346  94.54  96  94.1  442  94.4 
 Equivalence or Non-inferiority 20  5.46  6  5.9  26  5.6 
            
Total 368  100.0  102  100.0  470  100.0 
Abbreviations 






Supplement 5    Characteristics of Published CS-RCTs by Language of Bibliographic Databases 
 
Category 
English Databases  Chinese Databases  Total 
No.  %  No.  %  No.  % 
Positivity            
 Positive 285  72.5  38  50.7  323  69.0 
 Negative 108  27.5  37  49.3  145  31.0 
Sample Size            
 <100 147  37.2  37  49.3  184  39.2 
 >=100 248  62.8  38  50.7  286  60.8 
Number of Centers            
 Multi-center 123  31.1  25  33.3  148  31.5 
 Single-center 272  68.9  50  66.7  322  68.5 
Funding            
 Industry 76  19.2  17  22.7  93  19.8 
 Non-Industry 319  80.8  58  77.3  377  80.2 
Registration Type            
 Prospective 125  31.7  30  40.0  155  33.0 
 Retrospective 270  68.3  45  60.0  315  67.0 
Design            
 Superiority 371  94.4  71  94.7  442  94.4 
 Equivalence or Non-inferiority 22  5.6  4  5.3  26  5.6 
            
Total 395  100.0  75  100.0  470  100.0 
Abbreviations 
CS-RCTs: Chinese-Sponsored Randomized Controlled Trials 
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Appendix C: Supplementary Materials for Chapter 3 
 
Supplement 1 List of Trial Registries and Bibliographic Databases 
Trial Registries 
Primary Registries Recognized by the World Health Organization 
• Australian New Zealand Clinical Trials Registry (ANZCTR)  
• Brazilian Clinical Trials Registry (ReBec)  
• Chinese Clinical Trial Registry (ChiCTR)  
• Clinical Research Information Service (CRiS), Republic of Korea 
• Clinical Trials Registry - India (CTRI)  
• Cuban Public Registry of Clinical Trials (RPCEC)  
• EU Clinical Trials Register (EU-CTR)  
• German Clinical Trials Register (DRKS)  
• Iranian Registry of Clinical Trials (IRCT)  
• ISRCTN 
• Japan Primary Registries Network (JPRN)  
• Lebanese Clinical Trials Registry (LBCTR)  
• Thai Clinical Trials Registry (TCTR)  
• The Netherlands National Trial Register (NTR)  
• Pan African Clinical Trial Registry (PACTR)  
• Peruvian Clinical Trial Registry (REPEC)  
• Sri Lanka Clinical Trials Registry (SLCTR)  
• ClinicalTrials.gov 
Trial Registry by the China Food and Drug Administration 






• the Cochrane Central Register of Controlled Trials (CENTRAL) 
• the China National Knowledge Infrastructure (CNKI) 
• SinoMed 
• the VIP information 







Supplement 2    Search Strategies 
 
Strategy 1 Single-Center and Multi-Center CS-RCTs Registration Number 
Strategy 2 Single-Center and Multi-Center CS-RCTs PI's Name AND PI's Affiliation AND (Disease OR Drug) AND Study End Date 
Strategy 3 Multi-Center CS-RCTs Recruitment Facilities AND Disease AND Drug AND Study End Date 
PI: Principle Investigator; CS-RCT: Chinese-Sponsored Randomized Controlled Trials. 
 
Supplement 3    Search Terms 
 
Database Identifier Source of Subjects Source of Keywords 
English 
Disease MeSH Emtree 
Registry records 
PubMed entry terms 
Embase synonyms 
   
Drug MeSH Emtree 
Registry records 
PubMed entry terms 
Embase synonyms 
    
Chinese 
Disease MeSH (Chinese version) 
Registry records 
ICD-10 (Chinese version) 
ICD-9 (Chinese version) 
Three doctors from PUMC 
   
Drug MeSH (Chinese version) 
Registry records 
China FDA website for drug trade names and compound names 
Three pharmacists from PUMC 
MeSH: Medical Subject Headings; Emtree: Embase Subject Headings; ICD-9: The International Classification of Diseases, Ninth Revision; ICD-




Supplement 4    Method to Match Journal Articles with Registry Records 
 
Same Name of Experimental Drug and Targeted Disease, Same Registration Number 
Same Name of Experimental Drug and Targeted Disease, Same Ethics Committee Approval Number 
Same Details of Experimental Drug and Targeted Disease, Overlapped Study Period, Recruiting 
Centers and Authorship 
Same Name of Experimental Drug and Targeted Disease, Consistent Baseline Characteristics with a 
Match 
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